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ABSTRACT 
The human brain is generated by developmental events orchestrated by fine-tuned 
transcriptional events. The vulnerability of this process is highlighted by the fact 
that environmental insults in early stages of development, or germline mutations in 
chromatin remodelers, often lead to neurodevelopmental disorders. An historical 
challenge for studying neurodevelopmental disorders has been the lack of reliable 
human platforms. Nowadays, technological advancements allowed us to use human 
cellular models to study the neurons and the molecular implications of specific 
mutations. In this work is described a human modeling platform of Kabuki 
Syndrome, caused by germline mutations in the enzyme KMT2D, which is involved 
in enhancer activation, and of Gabriele-de Vries syndrome, caused by mutations in 
YY1, which mediates DNA looping between gene promoters and enhancers. These 
two diseases thus belong to the class of enhanceropathies. Using induced 
pluripotent stem cells and their differentiation in disease-relevant cell types such as 
neural crest stem cells and cortical excitatory neurons, it was possible to identify 
molecular and functional phenotypes unique to Kabuki syndrome that contribute to 
the understanding of its molecular pathogenesis. Moreover, starting from genetic 
observations of individuals with intellectual disabilities who lacked a molecular 
diagnosis, YY1 was identified as the mutated gene responsible for a novel 
neurodevelopmental disorder, which is caused by an improper regulation of 
transcriptional enhancers. The synergic study of enhanceropathies may lead to the 
identification of altered gene regulatory networks, convergent to common targets, 
responsible for shared clinical features, thus paving the way for the identification of 
shared actionable pathways. 
1 
 
INTRODUCTION 
Chromatin Structure and Epigenetics 
The genetic information is transmitted by the deoxyribonucleic acid (DNA) (Avery 
et al., 1944; Hershey and Chase, 1952), which in living beings is composed by the 
deoxyribonucleosides of the nitrogenous bases guanine (G) , cytosine (C), adenine 
(A), and thymine (T). DNA has a negative double helix structure, in which bases of 
the opposite strand interacts with hydrogen bonds. Guanine interacts with cytosine, 
and adenine with thymine by three and two hydrogen bonds, respectively (Watson 
and Crick, 1953).  
Genetic information can also be propagated from mother cell to daughter cell and 
from parents to offspring without changing the sequence of DNA, by the set of 
phenomena included in the term epigenetics. The term epigenetics (from the greek 
επί, epì = “above” and γεννετικός, gennetikòs = “genetics”) was originally used by 
Conrad Waddington in 1942, to describe the “causal interactions between genes 
and their products which bring the phenotype into being” (Waddington, 1942). 
Nowadays, a variety of meanings are included in this term: 
1) The set of phenomena responsible for the inheritance of a phenotype across 
generations (of a cell or individuals) without changes in nucleic acid sequence 
(Boniolo and Testa, 2012; Meloni and Testa, 2014); 
2) The mechanism by which a phenotype is stably maintained across the 
lifespan of an organism, including non-dividing cells (Beck et al., 2010). 
3) The use as synonymous of gene regulation and chromatin modifications (“On 
the use of the word ‘epigenetic,’” 2007) 
2 
 
In all the three definitions, the mechanism by which epigenetics is implemented is 
through DNA covalent modifications and/or by chemical modifications of proteins 
strictly associated with the DNA itself, such as histones. These molecular 
modifications are able to influence a phenotype, without varying the genotype, by 
influencing gene expression.  
There is a variety of DNA covalent modification, in animals the most relevant and 
studied one is the cytosine methylation in 5-methyl-Cytosine (5mC) (Aravind et al., 
2014). This modification has the peculiarity of not changing the pairing with G, 
consequently it does not introduce mutations when propagated through cell 
divisions, and influences gene expression. Cytosine is methylated by two de novo 
enzymes (DNMT3A and DNMT3B) and a maintenance methylase (DNMT1). 5mC 
cannot be directly removed. Indeed it can be diluted passively following cell division 
or it can be sequentially enzymatically oxidized to 5-hydroxymethylcytosine (5hmC) 
and to 5-formilcytosine (5fC) and 5-carboxylcytosine (5caC), which can be removed 
by the base excision repair (Jin and Liu, 2018). In eukaryotes, DNA resides in nuclei 
in chromatin: a molecular complex between DNA and proteins. The core unit of 
chromatin is the nucleosome, constituted by DNA wrapped in basic proteins called 
histones. The nucleosome includes  ∼147 bp, folded in 1.7 turns, and an octamer of 
histones composed by a pair of histones 3 (H3),  histone 4 (H4), histone 2A (H2A), 
and histone 2B (H2B) (Luger et al., 1997). Humans bear numerous histones 
isoforms, of them H2A is the most variable, with 19 genes; H2B has 16 variants; H3 
has 8 variants; H4 is encoded in multiple clusters but does not possess variants 
(Kamakaka and Biggins, 2005; Talbert and Henikoff, 2010). Post-translational 
modification of histones, as well as their isoforms, are involved in any cellular 
process such as gene expression regulation, DNA repair, cell cycle, recombination, 
apoptosis, and cell division (Lawrence et al., 2016). A linker histone, the histone 1 
(H1), is responsible for stabilizing the DNA around the nucleosome, promotes the 
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folding in a higher order of chromatin structure, and regulates cell cycle and gene 
expression, as well  (Cutter and Hayes, 2015). 
Transcriptional Enhancers  
Since the discovery of the Lac operon in Escherichia coli, it has become common 
knowledge that non-coding DNA sequences can directly regulate gene expression 
(Jacob and Monod, 1961). In prokaryotes, these sequences are located near the 
transcription start site (TSS) and are a binding site for activators or repressors, 
which quickly change gene expression as a consequence of the replacement of a 
nutrient, or to respond to environmental stimuli in each organism. In metazoans, 
transcription regulation ensures gene expression in a specific tissue at a specific 
developmental window, with the final result of the organization of a complex 
organism derived from a single cell. This time-space regulation is mainly mediated 
by transcriptional enhancers, which are short DNA sequences (∼100–1,000 bp) 
located in the same chromosome (in cis) of the target genes and are positioned at 
any distance from them, from close proximity up to megabases of distance (Long et 
al., 2016). Enhancers were identified and named in 1981, when the transient 
expression of rabbit β-globin gene in HeLa was massively increased if linked with a 
72bp repeated region of the early genes of SV40, independently from its distance or 
position with respect to the gene (Banerji et al., 1981). Transcriptional enhancers 
have a pivotal role in the multi-step highly regulated gene expression regulation, 
which is accompanied by chromatin reorganization, DNA modifications, and 
histone post-translational modifications (HPTMs). Given the heterogeneous nature 
and sparse distribution of enhancers, their direct identification is difficult. Using 
chromatin immunoprecipitation coupled with sequencing (ChIP-seq), histone 
modifications can be used to identify enhancers, their activation status and to 
distinguish them from promoters (ENCODE Project Consortium, 2012; Heintzman 
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et al., 2007; Visel et al., 2009).  The presence of histone 3 lysine 4 monomethylation 
(H3K4me1) identifies the presence of enhancers, which can be activated, when 
marked by histone 3 lysine 27 acetylation (H3K27ac), or poised if marked by histone 
3 lysine 27 trimethylation (H3K27me3) (Rada-Iglesias et al., 2011). Enhancers 
physically contact target promoters in a loop structure, that once is formed can be 
inherited during cell division and differentiation, to ensure that the target promoter 
will start and maintain the gene transcription only in the correct cell type and at 
right time(Ghavi-Helm et al., 2014; Jost et al., 2014). The loop structure is the result 
of the interaction between multiple structural proteins, such as cohesin, the 
mediator complex, YY1, histone modifiers, and chromatin remodelers (Hu and Tee, 
2017; Weintraub et al., 2017), as depicted in  
Figure 1. The important similarity between enhancer and promoters is even 
underscored by the capability of the RNA pol2 associated with enhancers to 
bidirectionally transcribed them, producing what are called enhancer RNA (eRNA), 
which are associated with enhancer activity (Tippens et al., 2018). These transcripts 
bind YY1 and have been shown to increase its recruitment at the enhancer site 
(Sigova et al., 2015). Nevertheless, they are not needed to sustain the transcription 
of target genes and are not accumulated (Rahman et al., 2017). While histone 
modifications are a reliable signal for the presence of enhancers, and their activation 
status, they do not reveal about the position of the target genes. For this reason, the 
identification of target genes is more difficult, primarily because enhancers can 
interact with multiple genes and are located anywhere in the same chromosome. 
Nowadays, next-generation technologies (NGS) have become helpful to develop 
sequencing techniques to identify interactions between enhancers and target 
promoters by chromosome conformation capture techniques and their 
modifications, such as HiC or HiChIP, to identify the contacts between the genomic 
target of a protein of interest and its distal targets (Davies et al., 2017; Mumbach et 
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al., 2016). Once identified, enhancers need functional validation. Classically, 
episomal reporters used were, but they fail to reproduce the appropriate chromatin 
context and they activate the INF-I response, for this reason, several techniques 
have been developed during years to increase the accuracy and reliability of such 
assays and to study such interactions in the native chromatin context (Fulco et al., 
2016; Inoue et al., 2017; Muerdter et al., 2018). 
 
 
Figure 1 GTF: general transcription factor; TF: transcription factors; eRNA: enhancer RNA; mRNA: 
messenger RNA 
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The Early Development  
The human development starts with the fusion of the two maternal and paternal 
gametes to form the zygote, the only totipotent cell, that it undergoes asynchronous 
sequential mitotic divisions. These cells, the blastomeres, divide for four days (E4) 
during which at 8-cell stage undergo compaction, a process by which they connect 
each other’s by tight gap junctions and they separate from the zona pellucida, further 
cell division will form the 16-cells stage called morula. The outer cells give rise to the 
trophoblast cells that at E5, during the cavitation process, secrete liquid inside 
forming the cavity called blastocele, characteristic of the new embryonic structure 
called blastocyst. Here, the trophoblast cells are clearly separated to the inner cell 
mass (ICM) cells, which are pluripotent. The trophoblast cells will give rise to the 
chorion and the embryonic portion of the placenta. Differently, the ICM cells will 
give rise to the embryo, yolk sac, allantois, and amnion. This first commitment step 
is regulated by the mutually exclusive expression of NANOG and OCT4 in the ICM, 
and CDX2 in the trophectoderm (Ralston and Rossant, 2005). After the 
implantation, at about E9 there is a second commitment event during which the 
ICM divides into the epiblast and the hypoblast. The epiblast cells are the last 
pluripotent cells: they will give rise to the three germ layers (endoderm, mesoderm, 
ectoderm), and to the amniotic ectoderm; the hypoblast will give rise to the yolk sac. 
During this commitment phase, the hypoblast express GATA6 that repress the self-
sustaining pluripotency core network composed by NANOG, OCT4, and SOX2 
(Boyer et al., 2005)  that are still expressed in the epiblast (Li and Belmonte, 2017). 
Between day E13 and E20 the embryo undergoes gastrulation, the process that the 
developmental biologist Lewis Wolpert defined as the most critical moment of life 
“It is not birth, marriage or death, but gastrulation which is truly the most 
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important time in your life”1. During this process, the three embryonic layers are 
formed by cell migration across the primitive streak and towards the rostral part of 
the embryo.  
The Neural Crest Stem Cells 
After the end of the third gestational week (3 GW) the embryo finishes the 
gastrulation and starts the process by which develops the central nervous system 
(CNS). A portion the dorsal mesoderm sends signals to the dorsal ectoderm which 
elongates its cells in columnar cells, forming the neural plate, which is negative for 
the pluripotency factors NANOG and OCT4 but still express SOX2, which is 
necessary to start neuronal differentiation and for neuronal progenitors 
maintenance (Zhang and Cui, 2014), and start to express PAX6 (Osumi et al., 2008). 
At E21 it starts the neurulation, the process during which the neural ridges (the 
regions that encompass the neural plate laterally) rise, fold and eventually fuse 
forming the neural tube. The closure starts in the middle region of the embryo and 
continues towards both the rostral and caudal region. The neural tube that is located 
above the notochord and below the epidermal ectoderm, to which exchanges 
morphogenetic signals. From this region, the neural crest stem cells (NCSC) are 
formed and start to migrate ventrally in multiple regions of the embryo according to 
their rostral-caudal positioning. The NCSC will give rise to a multiplicity of tissues 
and organs, for this reason, they are sometimes referred to as the “fourth embryonic 
layer” (Dupin et al., 2018). NCSC give rise to every component of the peripheric 
nervous system, the enteric nervous system, cranial nerves, and melanocytes.  The 
cranial neural crests give rise to the anterior facial cartilage and bones, adrenal 
                                                   
1 From Egg to Embryo: Determinative Events in Early Development (1999), Ch. 1 : 
Regional specification in animal development 
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gland. The cardiac NC give rise to the muscle-connective tissue wall of the large 
arteries and the septum, responsible for the separations of the pulmonary 
circulation from the aorta. Also, NCSCs contribute to teeth formation, thymus, 
parathyroid, and thyroid glands (Vega-Lopez et al., 2018) as summarized in Figure 
2. The class of diseases in which neural crest are affected is called neurocristopathies 
and, given the anatomical contribution of the NC, it is not surprising to find 
recurrent clinical manifestations such as craniofacial abnormalities, neurological, 
cardiac, and immunological dysfunction in such disease category. 
 
Figure 2 summary rapresentation of neural crest multipotency, adapted from Vega-Lopez et al., 2018 
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Central nervous system development 
After the completion of the neural tube, the neuronal progenitors form a single layer 
surrounding the hollow center. The rostral progenitors will give rise to the brain, 
while the neuronal progenitors in the caudal neural tube will give rise to the 
hindbrain and the spinal cord. This cavity will become the brain ventricular system, 
for this reason, this region is now called ventricular zone (VZ). Before the neural 
tube closure, the anterior end starts to develop the three brain vesicles 
prosencephalon, the mesencephalon, and rhombencephalon, which will form the 
forebrain, the midbrain, and the hindbrain, respectively, as depicted in Figure 3. At 
this stage, PAX6 is expressed only in forebrain, hindbrain, and spinal cord (Osumi 
et al., 2008), while OTX2, another important transcription factor that starts to be 
expressed at morula stage, is now expressed only in the forebrain and midbrain 
(Beby and Lamonerie, 2013).  
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Figure 3 Stages of central nervous system development from the neural tube. Adapted from Kandel – 
Principles of Neural Science 5th edition.  
 
The main changes in the brain morphology happen within the fetal period (e.g 
period between GW9 to the end of gestation) during which gyri and sulci are formed. 
During this period the neural progenitors expand their pool and differentiate in 
neurons. In particular, most of the neurons of the adult brain is formed by mid-
gestation (the time span that includes GW18-24). Neural progenitors divide 
symmetrically starting from the end of gastrulation (~ GW3) to GW6. Afterward, 
there is a switch to asymmetrical divisions, by which each progenitor gives rise to a 
neuronal progenitor and a post-mitotic neuron.  
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The neocortex development 
The neocortex is the part of the CNS responsible for behavior and cognition; it is 
composed of six stratified layers of organized neurons, generated from proliferative 
waves of migrating neurons in contact to the VZ. The neocortex is indeed one of the 
most complex areas of the human brain, and it is remarkably different from other 
specie ones. This structure was first identified in reptiles during the Carboniferous 
Period, and it has increased in size and connectivity complexity during evolution. 
There are important anatomical and functional differences between the human 
neocortex and the most studied mammalian model Mus musculus one, especially in 
the prefrontal cortex structure, which constitutes almost one-third of the neocortex 
and it is responsible for complex cognitive tasks (Carlén, 2017). The neocortex is 
composed of neurons that migrate from the proliferative zone in the VZ towards the 
pial surface, generated in sequential migratory waves. The first migratory neurons 
contact the pial surface and generate the preplate (PP). The second migratory wave 
splits the PP into the subplate (SP) and the marginal zone (MZ), which contain the 
Cajal-Retzius cells (CR). The CR cells produce Reelin, which controls the positioning 
of migrating neurons stopping their migration. Consequently, every following 
neuronal migratory wave will get through the most upper layer taking its place in 
the developing neocortex. For this reason, apart from the very first migratory wave, 
the neocortex possesses an inside-out structure in which the oldest neurons are the 
closest to the VZ. The cell called “radial glial guides” was initially thought to support 
neuronal migration from the VZ to the pial surface thanks to their long process 
extended from the VZ to the pial surface (Rakic, 1972), was later revealed to be the 
asymmetrical neuronal progenitor, which possesses the ability of replicating both in 
the VZ and in the sub-ventricular zone (SVZ) (Noctor et al., 2004, 2001). The 
neocortex structure with developmental stages is represented in Figure 4. 
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Figure 4   Representation of the inside-out cortical layer development. NESC: neuroepithelial stem cells, divide 
symmetrically; RGPC: radial glia progenitor cells, divide asymmetrically. PP: preplate; VZ: ventricular zone; 
SVZ sub-ventricular zone; MZ: marginal zone; CP: cortical plate;  SP: subplate; IZ:intermediate zone; WM: 
white matter; I-VI: cortical layers 1-6. Color code represent proliferative and migratory waves. Adapted from 
Nguyen and Hippenmeyer – Cellular and Molecular Control of Neuronal Migration, Springer, 2014. 
 
 The final neocortex is not only formed by neurons originated from the described 
proliferative zone, indeed, it is also composed by the interneurons that tangentially 
migrate to the neocortex from a proliferative region in the lateral and medial 
ganglionic eminences, comprised between the VZ and the striatum (Stiles and 
Jernigan, 2010). The transcription factors Ngn1 and Ngn2 (NEUROG2, 
Neurogenin-2) have a critical role in the differentiation of the glutamatergic cortical 
neurons, and they represses the GABAergic phenotype (Schuurmans et al., 2004). 
Figure 5 summarizes the developmental origin of cortical excitatory neurons and 
GABAergic neurons.  
 
. 
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Figure 5 Transcription factors involved in the generation of glutamatergic or GABAergic interneurons. MGE: 
medial ganglionic eminence; LGE: lateral ganglionic eminence. Adapted from Kandel – Principles of Neural 
Science 5th edition. 
  
Neurodevelopmental disorders and chromatin biology 
dysregulation 
Neurodevelopmental disorders (NDDs) are a vast class of early onset neurological 
diseases that encompass intellectual disabilities (ID), autism spectrum disorders 
(ASD), attention-deficit/hyperactivity disorder (ADHD), schizophrenia, bipolar 
disorder, learning disabilities, and major depressive disorder. NDDs are caused both 
by environmental factors (such us alcohol consumption during pregnancy, causing 
the fetal alcohol syndrome) and genetic factors. It is difficult to estimate a precise 
incidence and prevalence of NDDs, especially concerning IDs, since it is identified 
by IQ tests, which are often heterogeneous and not accurate (Ropers, 2010). It has 
been estimated that de novo mutations in coding sequence explain 42% of cases of 
severe NDDs with a prevalence mean of 1 in 295 birth caused by dominant 
monogenic de novo mutations in the coding sequence of genes, of which 59% 
operate by loss of function and 41% by altered function (Deciphering Developmental 
Disorders Study, 2017). Concerning de novo single nucleotide variants (SNVs) in 
non-coding elements such as fetal brain-active elements and highly conserved 
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elements, it has been estimated that they account for 1-3%  and 0,5% of NDDs, 
respectively (Short et al., 2018).  It then emerges the importance of regulatory 
elements for the molecular pathogenesis of these diseases. Indeed, taking in account 
the list of 910 genes responsible for ASDs (January 2018), provided by the Simons 
Foundation Autism Research Initiative (SFARI)2, it emerges the gene ontology (GO) 
enrichment “chromatin binding proteins”, preceded by three categories of 
molecular functions involved in neuronal biology, as shown in Figure 6  (Gabriele et 
al., 2018).  At the current state of knowledge, it is known that germline mutations in 
genes coding for chromatin remodelers, histone post-translational modifiers, and 
DNA methylases causes NDDs (Figure 7). To highlight the importance of these genes 
and of transcriptional fine regulation in the onset of NDDs it is possible to observe 
their spatial and temporal expression pattern in the brain. The region with the 
highest expression pattern of these genes is the brain cortex, in particular in the 
Brodmann area 9, located in the prefrontal cortex, known to be involved high 
cognitive functions and frequently disrupted in several NDDs. The temporal 
expression pattern further underscores their importance for neurodevelopment. 
Most of them show an increased expression pattern during the gestational period 
(e.g. the timespan between conception and GW8) and the fetal period (e.g period 
between GW9 to the end of gestation, and comprises the midgestation, which 
include GW18-24), which are thought to be the most susceptible developmental 
stage for neocortex development Figure 8  (Gabriele et al., 2018; Stiles and Jernigan, 
2010). 
 
                                                   
2 https://www.sfari.org/resource/sfari-gene/ 
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Figure 6 Gene Ontology analysis of SFARI genes responsible for ASDs, adapted from Gabriele et al., 2018 
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Figure 7 Representation of several genes coding for protein involved in chromatin remodelling, DNA 
methylation, and histone post-translation modifications and relative syndromes caused by germline 
mutations. Adapted from Gabriele et al., 2018 
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Figure 8 A) Spatial expression pattern according to the GTEx brain tissues; B) representation of spatial 
expression pattern; C) Temporal expression pattern according to the BrainSpan atlas. Adapted from Gabriele 
et al., 2018 
Disease Modelling and Induced Pluripotent Stem Cells 
The study of NDDs has the significant limit of lacking a proper model to study their 
molecular pathogenesis. As described above, the brain is a sophisticated and 
complex organ, several aspects of its functionality such as the processes of decision 
making, the molecular basis of learning and memory, or how the neuronal circuits 
elaborate information are still needed to be addressed (Adolphs, 2015). A reason for 
this limit is that some peculiarities are uniquely present in humans, but they are 
studied in model organisms, as surrogates, for the lack of availability of a human 
model, for obvious ethical reasons. Direct access to the human brain and its use as 
specimen is possible only using post-mortem samples. Even to test the existence of 
human adult neural stem cells, researchers had to used post-mortem tissues, taken 
from cancer patients treated with BrdU for diagnostic purposes (Eriksson et al., 
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1998).  Especially for the study of developmental diseases, it is obvious the 
impossibility of experimenting in humans.  However, it is important to address 
certain questions in the right cell type of the most appropriate organism.   
Nowadays, thanks to the isolation of embryonic stem cells (ESC) from the ICM of 
the embryonic blastocyst, both from mouse and human (Evans and Kaufman, 1981; 
Thomson et al., 1998),  it is virtually possible, using the knowledge coming from 
decades of developmental biology, to differentiate  ESC in any cell type present in 
an organism (Vazin and Freed, 2010). For this reason, stem cell biology permitted 
to reproduce in vitro human developmental processes that were not possible to 
study before. It is now possible to study the onset and molecular pathology of 
diseases for which a model was not present (Craft and Johnson, 2017). Nevertheless, 
the use of human ESC raises the ethical issue of the sacrifice of a human embryo, a 
possible future individual. Moreover, given the limited availability of hESC clones, 
strictly connected to the ethical concerns of deriving them, while they are a good 
model for basic molecular studies, the lack of biological replicates becomes a 
problem for drug screening studies, in which individual genotypes can interact with 
drug metabolism. In addition, the clinical potential of hESC is impaired by the 
immunological response of the receiver, given the differences in the 
immunohistocompatibility complexes. Another issue of hESC is that they represent 
a human being that was never formed. Consequently, any information regarding 
phenotypes is not possible to be inferred (Ilic and Ogilvie, 2017). The solution to all 
these problems was obtained by Shinya Yamanka, when in 2006 identified the 
cocktail of transcription factors Oct3/4, Sox2, Klf4, and c-Myc (Takahashi and 
Yamanaka, 2006) able to reprogram adult somatic cells back to  induced pluripotent 
stem cells (iPSCs) with the property of contributing to all the three embryonic layers 
and germline of mice, if positive for Nanog (Okita et al., 2007). A short time was 
needed to replicate the result also in human (Takahashi et al., 2007). The first 
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generations of iPSC were not devoid of problems, such as the use of integrative 
vectors for the delivery of the expression cassette and the use of the oncogene c-Myc, 
which confers oncogenic potential (Hyun et al., 2007). Research has overcome these 
problems by using non-integrative methods, as the use of the self-replicating RNA 
viruses Sendai virus (Fusaki et al., 2009) and the backbone of the Venezuelan 
Equine Encephalitis (VEE) (Yoshioka et al., 2013) to solve the integration problems, 
and by substituting the oncogene c-Myc by the maternal factor GLIS1 (Nakagawa et 
al., 2008). 
Kabuki Syndrome 
Kabuki syndrome  (KS) is a rare multisystemic neurodevelopmental disorder first 
described in 1981 (Kuroki et al., 1981; Niikawa et al., 1981). KS prevalence is 
estimated to be 1/33000 (Adam and Hudgins, 2005). It is a dominant, autosomal 
genetic disease, and a heterogeneous clinical phenotype characterizes it. 
KS clinical phenotype features characteristic facial dimorphisms, which encompass 
long palpebral fissures with eversion of the eyelid, arched eyebrows, a short 
columella with a depressed nasal tip and prominent ears. Moreover, KS is 
characterized by mild to moderate mental retardation. Also, KS includes postnatal 
growth retardation and short stature, skeletal abnormalities, fetal fingerpads, cleft 
lip and/or palate. Additionally, KS encompasses functional abnormalities such as 
seizures, hearing loss, feeding problems, endocrinologic alterations such as 
premature thelarche in females, increased susceptibility to infections such as Otis 
and also autoimmune disorders (Kuroki et al., 1981; Niikawa et al., 1981). 
Furthermore, KS patients have been described to have congenital heart defects 
(Ohdo et al., 1985); the most common alterations are the juxtaductal coarctation of 
the aorta, the ventriculoseptal defect, and atrial septal defects (Digilio et al., 2001; 
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Hughes and Davies, 1994). More than 25% of patients have been reported to have 
renal anomalies such as malposition of the kidneys, renal hypoplasia or dysplasia, 
hydronephrosis, and fusion defects of the kidneys (Ilyina et al., 1995; Kawame et al., 
1999; Niikawa et al., 1988). Interestingly, most of the systemic KS clinical anomalies 
can be traced back to a neural crest embryological origin (Vega-Lopez et al., 2018).  
Even the cardiac embryological defects can be traced back to alterations in cardiac 
neural crest (Kappetein et al., 1991; Keyte and Hutson, 2012).   
The genetic cause of KS was unknown until 2010 when KMT2D3 was identified as 
the gene primarily mutated (Ng et al., 2010) to cause the syndrome. Moreover, 
mutations of KDM6A4 were later identified as responsible for being causative of KS 
in a minor percentage of cases (Lederer et al., 2012).  
Mutations in KMT2D and KDM6A explain 60-70% and 10% of KS cases, 
respectively; the remaining cases are caused by a mutation in unidentified genes 
(Miyake et al., 2013).  Knockdown experiments, with morpholino, in D. rerio, 
underlined the involvement of KDM6A and KMT2D in the development of brain and 
heart and recapitulated the craniofacial anomalies typical of KS (Van Laarhoven et 
al., 2015). According to the cardiological clinical phenotype, KMT2D has been found 
to regulate heart development in a KO mouse model. Mice with only one Kmt2d 
allele were viable and with mild defects in the ascending aorta; KO mice embryos 
lacked somites and headfolds at E8.0. Interestingly this study suggests that KMT2D 
is mainly involved in cardiac development through H3K4me2 deposition (S.-Y. Ang 
et al., 2016). 
                                                   
3 In current literature, the gene coding for KMT2D can be found with many synonyms’: ALR, 
CAFL114, MLL4 and MLL2. To avoid any confusion, I will refer to histone modifiers only according 
to the nomenclature proposed by Allis et al. (Allis et al., 2007). 
4 Already known as UTX. 
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KMT2D gene 
KMT2D resides on chromosome 12q13.12 and codes for the lysine 4 histone 3 
(H3K4) methyltransferase KMT2D, a 5537 amino acids 593 KDa protein containing 
at the Amino-Terminal Domain (NTD) 2 plant homeotic domains (PHDs) clusters, 
containing three PHDs each cluster (Ruthenburg et al., 2007). Also, at the 
Carboxyterminal domain (CTD), KMT2D contains a SET catalytical domain, 
another PHD, and an FY-rich N/C-terminal (FYRN and FYRC) domain. Moreover, 
it includes nine nuclear receptor interacting motifs (LXXLLs) and a high mobility 
group (HMG-I) (Froimchuk et al., 2017).  
KDM6A gene 
KDM6A is located on the X chromosome but escapes its inactivation (Greenfield et 
al., 1998). It codes for a protein composed of 1401 aminoacidic residues, which 
weights around 154KDa. The NTD contains tetratricopeptide repeats, which are 
known to mediate protein-protein interactions (Smith et al., 1995) while at the CTD 
contains a treble-clef zinc finger, that may be involved both for DNA binding or 
protein-protein interactions (Ginalski et al., 2004). KDM6A is the only demethylase, 
together with KDM6B5, able to counteract the post-translational modification 
performed by the Polycomb Repressive Complex 2 (PRC2) by performing di- and 
trimethyl H3K27 demethylation with the JmjC-domain (Agger et al., 2007; Lan et 
al., 2007). The Y chromosome hosts a KDM6A homolog named UTY, which is 
known to be catalytically dead (Hong et al., 2007). Its presence is necessary, since 
female Kdm6a KO mice die during embryonic development E11.5-12-5 (Shpargel et 
al., 2012; Wang et al., 2012). 
                                                   
5 Already known as JMJD3. 
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KMT2D and UTX function in KMT2D/COMPASS complex 
KMT2D fulfills its role in the KMT2D/COMPASS (COMplex of Proteins ASsociated 
with Set1) complex, an evolutionally conserved multi-subunit complex able to 
perform H3 post-translational modifications. The methylase catalytic core of the 
COMPASS complexes are the enzymes KMT2. In mammals, there are six different 
H3K4 methylases (KMT2A-G, excluding the catalytically inactive KMT2E), which 
arise from duplication events occurred during evolution. In comparison to 
Drosophila melanogaster, KMT2A/B proteins are homologous of Trithorax (Trx); 
KMT2C/D of Trithorax-related (Trl) and KMT2F/G of Set1. In relation to yeast, Trx, 
Trl, and Set1 of D. melanogaster derive from the yeast Set1. While Set1 in yeast is 
able of catalyzing all the three methylation status of H3K4, together with the 
duplication, the metazoan COMPASS complexes acquired the ability to catalyze 
specific methylation status, with different regulatory function (Mohan et al., 2011; 
Shilatifard, 2012).  In metazoan, the COMPASS complexes share a set of core 
subunits and contain a set of complex specific ones. The subunits common to all the 
COMPASS complexes are ASH2L and RBBP5, which interact and activate all the 
KMT2 family proteins (Li et al., 2016); WDR5, which binds the FYRN/FYRC 
domains of KMT2C and KMT2D  (Cho et al., 2007); and DPY30. The specific 
subunits of the KMT2D/COMPASS complex are PTIP, PA1, NCOA6, and KDM6A,  
the histone demethylase able to remove the lysine 27 histone 3 tri-methylation 
(H3K27me3) (Kruidenier et al., 2012). Initially, KMT2D was first purified from 
HeLa nuclear extracts and was shown to belong to the “ASCOM” complex, together 
with ASH2L, NCOA66, RbBP5, and KMT2C (Goo et al., 2003). A later study on PTIP-
associated proteins shown that endogenous PTIP interacts with ASH2L, RbBP5, 
WDR5, DPY30, NCOA6, KDM6A, PA1, KMT2C, and KMT2D. Furthermore, it was 
                                                   
6 Called ASC-2 in the reference. 
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shown that PTIP and PA1 associate In the same protein complexes, which contain 
KMT2D or KMT2C and they exhibit robust H3K4 methylation activity (Cho et al., 
2007). Additionally, during the same period, independent research corroborated the 
same discoveries (Issaeva et al., 2007; Patel et al., 2007).  
Following ChIP-chip experiments of KDM6A in lung and foot fibroblasts, 92% of 
binding events were found to occupy HOX loci selectively, both in transcriptionally 
active and inactive HOX genes. Conversely, in mouse ESC ChIP-chip KDM6A was 
excluded from HOX genes, which are inactive and marked by H3K27me3 (Lan et al., 
2007). In parallel, independent research showed the KDM6A role in HOXA1/3 and 
HOXB1/3 activation, following retinoic acid treatment in pluripotent testicular 
embryonal carcinoma cell line NT2/D1 (Agger et al., 2007; Lee et al., 2007).  
Moreover, it has shown that after retinoic acid administration, H3K27 
demethylation and of PRC2 occupancy decrease in the promoter regions of 
HOXA1/3 and HOXB1/3, and it is subsequent to ASH2L recruitment and increase 
in H3K4me3 (Lee et al., 2007). Since both KDM6A and KMT2D are in the same 
molecular complex, it is not surprising that also KMT2D was found to be required 
to mediate retinoic acid response on its target genes (Guo et al., 2012). Afterward, 
the interaction with the retinoic acid receptor (RAR) was found to be mediated by 
the KMT2D/C COMPASS complex subunit NCOA6 (Rocha-Viegas et al., 2014).  
Moreover, estrogen receptor alpha (ERα), in the presence of its ligand, interacts 
directly with KMT2D thanks to its LXXLL motifs and triggers the localization of 
KMT2D to promoter regions of estrogen target genes, which are activated (Mo et al., 
2006).  
Nowadays, the research identified KMT2D as responsible for the deposition of the 
mono-methyl group on H3K4 (H3K4me1), a hallmark of enhancer regions, while 
not being directly involved in H3K4me3 (Lee et al., 2013a).   
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It is now known that the demethylation conducted by KDM6A makes H3K27 a 
substrate for p300/CBP acetylation (H3K27Ac), which is recruited by KMT2D 
(Wang et al., 2016). Consequently, the combined action of KMT2D and KDM6A is 
required to control cell fate transition, as shown in macrophages and ESC 
(Kaikkonen et al., 2013; Wang et al., 2016), by changing the enhancer status to an 
active state, which is defined by the presence of H3K4me1 and H3K27Ac whilst 
lacking H3K4me3 and H3K27me3 (Creyghton et al., 2010; Heintzman et al., 2007; 
Rada-Iglesias et al., 2011). Additionally, KMT2D/C are required for priming of 
enhancers and super-enhancers during cell differentiation of mouse brown adipose 
tissue, followed by their activation by CBP/p300 binding (Lai et al., 2017).  
As with KMT2A and B, KMT2C and KMT2D have a partially redundant role: the 
deletion of either one of these two genes affects global H3K4me1 deposition only 
marginally. Mice model for Kmt2c and Kmt2d have phenotype onset remarkably 
different: Kmt2c depleted mice die after birth without morphological alterations, 
whereas Kmt2d KO mice die during embryonic development, at embryonic stage 
E9.5, due to its essential role in heart development, adipogenesis, and myogenesis. 
Accordingly, conditional KO in cardiac precursor and myocardium leads to 
embryonic lethality for severe cardiac defects (Siang-Yun Ang et al., 2016). 
Moreover, the conditional depletion of Kmt2d in the somatic precursor showed 
decreased brown adipose tissues formation and muscle mass levels, leading the mice 
to die by breathing dysfunction after birth (Lee et al., 2013a). Similar observations 
were reproduced after knocking down, by morpholino experiments, KMT2D and 
KDM6A orthologs in Zebrafish. The authors observed their involvement in the 
heart, brain, and craniofacial development (Van Laarhoven et al., 2015).  
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KMT2D and KDM6A enzymatic-independent role 
There is convergent evidence pointing to the fact that the role of KMT2D and 
KDM6A is not solely restricted to their catalytical activity. Indeed, research has 
shown an enzymatic-independent role for both.  The presence of the SET domain in 
KMT2D it is not only essential for the catalytic activity but also for the stability of 
the protein. The catalytical activity is dispensable for mediate long-range 
interactions and promoting enhancer RNA (eRNA) transcription. Indeed, the loss 
of KMT2D catalytic activity only marginally impacts target gene expression and 
H3K27Ac deposition (Dorighi et al., 2017; Jang et al., 2017). However, the presence 
of KMT2D itself is essential to prevent the KMT2D COMPASS Complex to collapse 
and for KDM6B stability (Jang et al., 2017; Lee et al., 2013a).   
In support to the hypothesis that these enzymes have alternative role than their 
catalytical activity, it is necessary to underscore that KS individuals have been found 
mutated in KDM6A both in females and males, which have only one copy (Banka et 
al., 2015; Lederer et al., 2012). As with KMT2D, also KDM6B catalytical activity has 
been found to be dispensable for enhancer activation and cell-type specific gene 
transcription for mammary luminal differentiation and C. elegans development 
(Vandamme et al., 2012; Yoo et al., 2016). These evidence permits to speculate that 
if KDM6A have an independent role from its catalytical activity, also the paralogue 
UTY7 might have a similar role and might compensate for KDM6A loss in male KS 
individuals. Indeed, mouse UTY can compensate for Kdm6a deletion and can rescue 
development. The UTY function is independent of catalytical activity since both in 
vitro assay with the human UTY (Agger et al., 2007; Lan et al., 2007) and in vivo 
experiments with the mouse one showed its lack of enzymatic activity (Shpargel et 
al., 2012). KDM6A and UTY have redundant function in embryonic development, 
                                                   
7 While KDM6A resides on the X chromosome, UTY is located in the Y chromosome.  
26 
 
and they both influence the deposition of H3K4 methylation since also UTY, 
interacting with RBBP5, is included in the KMT2D compass complex (Shpargel et 
al., 2012). Also, UTY partially recover NC conditional KO of Kdm6A phenotype, 
which appears to be majorly involved in NC post-migratory developmental stage 
(Shpargel et al., 2017) 
A convergent line of evidence suggests that the enzymatic-independent function of 
KMT2D, KDM6A, and UTX is mediated by their ability to interact with chromatin 
remodelers of the SWI/SNF family. Indeed, both KDM6A and KDM6B have been 
found to mediate the interaction between the catalytical subunit of the SWI/SNF 
complex Brg18 and the transcription factor T-bet, of the T-box family (Miller et al., 
2010).  Moreover, also UTY has been found to interact with BRG1 (Shpargel et al., 
2012). In addition, both wild-type and enzymatically inactive KDM6A have been 
found to mediate the interaction between Brg1 and Tbx5, and to facilitate Brg1 
recruitment to the enhancers of the cardiac genes ANF and Baf60c (Lee et al., 2012). 
In addition to the interaction with Brg1, KDM6A has been found to directly bind, 
together with SMARCA2, to the first conserved zinc fingers of CBP by its TRP 
domains (Tie et al., 2012, p. 27). Moreover, both the SET domains of KMT2D and 
KMT2C have been found to directly interact with SMARCB1 (Lee et al., 2009). 
Finally, elegant research has shown that neither KMT2D nor KDM6A catalytical 
activities are necessary for gene activation, but it is their cooperativity with p300 
that stimulates mostly target gene expression (Wang et al., 2017).  The most updated 
model for the mechanism of the KMT2D COMPASS complex is summarized in 
Figure 9. 
                                                   
8 In human SMARCA4 
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Figure 9 model for KMT2D COMPASS complex function. MLL4C: MLL4 complex; UTX: KDM6A; RARE: 
retinoic acid response elements. Adapted from Wang et al., 2017 
  
Altogether, these piece of research, support the involvement of KMT2D and KDM6A 
in the etiology of KS but they are not explaining the clinical phenotype with an 
identification of the downstream targets altered as consequence of the heterozygous 
deletion of one of the two genes.  Heterozygous mice for Kmt2d display increased 
serum bile acid, glucose tolerance, and insulin sensitivity and in this animal model 
Kmt2d was shown to regulate the hepatic circadian clock (Kim et al., 2015). 
Moreover, following studies highlighted the role of Kmt2d as an epigenetic mediator 
of overnutrition-induce murine steatosis (Kim et al., 2016).  
Nowadays, research is defining a new class of diseases demarcated by alteration of 
enhancer regulation, and it is referring to this class as enhanceropathies (Smith and 
Shilatifard, 2014). Consequently, due to the players involved in KS, this syndrome 
can be included in this category. An altered stoichiometry of KMT2D/COMPASS 
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complex is relevant for the pathogenesis of KS, and it has already been shown that 
fine regulation of PRC2 axis is a key feature in neurodevelopment (Burgold et al., 
2012, 2008; Fragola et al., 2013; Park et al., 2014; Testa, 2011). For these reasons, 
and as mentioned before, due to the importance of the integer presence of KMT2D, 
to better study a cellular model that can recapitulate KS pathogenesis, it is 
interesting to analyze the impact of KMT2D haploinsufficiency.  
KMT2D mutations in cancer 
Over the last years, KMT2D has emerged as one of the most frequently mutated 
genes across a wide spectrum of cancers, with a driver role in the majority of them 
(Kandoth et al., 2013; Pasqualucci et al., 2011; Rao and Dou, 2015). In normal cells, 
the KMT2D loss is associated with malignant transformation, and it is thought to be 
a tumor suppressor (Ford and Dingwall, 2015). Furthermore, high levels of KMT2D 
are related to poor prognosis in breast cancer patients (Kim et al., 2014). Conversely, 
KMT2D deletion in proliferating transformed cells have antiproliferative effect as it 
has been shown after its knockdown cancer cell lines (Guo et al., 2013). 
Moreover, KMT2D is the most mutated chromatin modifier in medulloblastoma and 
it has a role in its biology (Northcott et al., 2012). Also,  KMT2D has shown as a 
necessary regulator of metastatic melanoma cell migration (Bossi et al., 2016). More 
recently, acute deletion of KMT2D has been associated with genomic instability 
selectively affecting actively transcribed genes, thus providing a suggestive link 
between its enhancer-marking function and the preservation of genome integrity 
(Kantidakis et al., 2016). Surprisingly, although nearly three-quarters of KMT2D 
mutations in KS have the same pattern of domain loss to of the somatic cancer 
mutations (Rao and Dou, 2015), nowadays there is no association between KS and 
cancer. It is worthy of mention that also KDM6A is found mutated in several tumors 
and thought to work as a tumor suppressor, in part by counteracting PRC2 (Ezponda 
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et al., 2017, 2017; van Haaften et al., 2009). Unexpectedly, the incidence of cancer 
in KS has not been found to be increased in comparison to the general population. 
Nevertheless, some case reports show cancer occurrence in few KS individuals, and 
the authors invite the clinical community to carefully examine KS patients for 
malignancy (Bernier et al., 2017; Roma et al., 2015; Tumino et al., 2010).  
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YY1 haploinsufficiency syndrome  
After the first identification of an individual with ID carrying a YY1 de novo mutation 
(Lisenka E L M Vissers et al., 2010), an international clinical effort discovered 
additional 23 ID individuals with de novo YY1 mutations (Gabriele et al., 2017). YY1 
haploinsufficiency syndrome is a rare autosomal dominant ND, following defined 
by the OMIM committee as  Gabriele-De Vries syndrome9  (GADEVS). People with 
YY1 mutations share ID with variable cognitive impairment, dysmorphic facial 
features, delayed psychomotor development, feeding problems, and movement 
abnormalities. The facial dysmorphism shared among individuals included facial 
asymmetry with a broad forehead, an upper-lip indentation shaped like a Gingko 
leaf, and fullness of the upper eyelids. In the represented cohort, half individuals 
displayed behavioral anomalies like anxiety and autistic features. Few patients 
featured dystonia and a variety of congenital abnormalities, such as esophageal 
atresia, cleft palate, hydronephrosis, craniosynostosis, and Epstein anomaly 
(Gabriele et al., 2017). 
YY1, gene description and function 
YY1 is located on chromosome 14q32.2 and it codes for an ubiquitous (Patten et al., 
2018) zinc finger protein of 414 amino acids (Shi et al., 1991). It is homologous of 
the D. melanogaster Pleiohomeotic gene, which codes for a transcription factor able 
to mediate the recruitment of Polycomb Group (PcG) proteins to the Polycomb 
Responsive Elements (PRE) on DNA  (Brown et al., 1998). YY1 was named after the 
Yin-Yang, the Lao Tsu idea of equilibrium, given the fact that, in mammals, YY1 was 
initially found to function both as activator and repressor. It was first described that 
                                                   
9  OMIM: #617557 
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in presence or absence of the adenovirus E1A oncoprotein it represses or activates, 
respectively, the adeno-associated virus (AAV) P5 promoter (Shi et al., 1991). 
Following the line of research on Drosophila, initially YY1 was studied as PRC2 
interactor and was thought to mediate its repression. Several pieces of research have 
showed YY1 interaction with PRC2 and reported a possible role as repressor. 
However, most pieces of research show YY1 as an activator, especially in nervous 
system development (He and Casaccia-Bonnefil, 2008). The first piece of research 
in which unbiased genome-wide analysis were performed  suggested YY1 to have a 
major involvement in gene activation of highly transcribed genes, while having a 
negative role in nuclear and nucleolar small non-coding RNAs biogenesis, in mouse 
ESCs (Vella et al., 2012). Moreover, by mass-spectrometry analysis, no protein of 
the Polycomb-group was found to immunoprecipitated with YY1, in mESC (Vella et 
al., 2012). Nowadays, the functional role of YY1 seems to be clarified and can be 
compatible both with the activating and repressive reports. Indeed, YY1 mediates 
the formation of the structural loop between enhancer and promoters (Weintraub 
et al., 2017). Literature showing YY1 as repressor can be compatible with the later 
description of poised enhancer (Calo and Wysocka, 2013). For example, in 
myoblasts, together with PRC2, YY1 occupies MyoD promoter, which is then 
expressed in myotubes. YY1 removal, even if it is associated with H3K27me3 
decrease, was not triggering gene activation (Caretti et al., 2004). Indeed, it is not 
YY1 per se function to activate or repress a gene, but the interactors associated with 
a chromatin loop. YY1 main interactors are p300/CBP (Lee et al., 1995), the INO80 
chromatin remodeling complex, as well as the two RNA helicases Ddx5 and Ddx3x 
(Cai et al., 2007; Vella et al., 2012; Wu et al., 2007). A recent study, in which eQTL 
were analyzed in 25 tissues, showed YY1 to have predominantly an activating role  
(Reshef et al., 2018).   
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Moreover, as well as other transcription factors, YY1 binds RNA and it has been 
shown to mediated X-chromosome inactivation by binding Xist RNA (Jeon and Lee, 
2011) and by promoting Xist expression (Makhlouf et al., 2014). The N-terminal 
region is responsible for the RNA-binding property of YY1, which make it capable of 
binding enhancer RNAs (eRNA) of active enhancers and DNA of promoters. For this 
reason, it has been proposed that RNA contributes to stabilize YY1 occupancy in 
regulatory elements (Sigova et al., 2015). A further study has shown that also the 
Zinc Finger domain is capable of binding RNA, with low specificity (Wai et al., 2016).  
While YY1 homozygous deletion results in embryonic lethality, the pleiotropy of YY1 
haploinsufficiency has been already shown in a mouse model. Its heterozygosity 
leads to serious growth retardation, proliferative and neurological defects such as 
exencephaly, pseudoventricles, and asymmetry of the developing brain, even though 
at incomplete penetrance (Donohoe et al., 1999).  Other lines of research have 
underscored the direct relevance of YY1 for neuronal development (He and 
Casaccia-Bonnefil, 2008). Indeed, YY1 activity is necessary for oligodendrocytes for 
global nerves myelination (He et al., 2007) and in Schwann cells, where it mediates 
the myelination gene expression program neuregulin-dependent (He et al., 2010). 
Moreover, recent research has showed that YY1 knockdown impairs enhancer-
promoter interactions of neuronal progenitor cells regulators (Beagan et al., 2017).  
 
 
 
 
33 
 
Aim of the Thesis 
An historical challenge for studying neurodevelopmental disorders has been the lack 
of reliable human platforms. Especially the human brain has anatomical and 
functional properties that are not possible to reconstruct in animal models. This has 
always constituted a major challenge for the study of neurodevelopmental disorders. 
Only recently it was possible to study this class of diseases in human reliable and 
informative cellular models (Linda et al., 2018). Moreover, the molecular diagnosis 
of neurodevelopmental disorders caused by rare sporadic germline mutations, and 
the understanding of their molecular impact, it has become possible only recently 
thanks to the development of next-generation sequencing techniques. In this work 
I pursued two connected line of research:  
I) the generation of a reliable human model for KS, and the study of the 
molecular and functional impact in primary cell types, at the pluripotent 
stage, and in disease-relevant cell types such as NCSC, and cortical 
neurons;  
II) II) defining the molecular mechanism underlying the intellectual 
disability caused by mutations in YY1, and the generation of a disease 
modeling platform based on iPSCs, which will permit us to study the 
impact of YY1 mutations in specific disease-relevant cell types in the 
future. 
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MATERIAL AND METHODS 
Cell Culture 
Fibroblasts were cultured in RPMI 1640, FBS 15%, L-Glutamine 1%, Penicillin-
Streptomycin 1%.  Trypsin was used to passage fibroblasts. iPSCs were cultured with 
mTeSR-1 (StemCell Technologies) or Essential 8 (E8, Thermo fisher) in feeder-free 
conditions on hES-qualified Matrigel (BD Biosciences) diluted 1:40. iPSCs were 
passaged with ReLSR (StemCell Technologies). Accutase (Sigma) was used when 
single cell for counting were needed, supplementing the medium with rock inhibitor 
5 μM Y-27632 (Sigma. NCSC were cultured with a defined medium as previously 
described (Menendez et al., 2013). Cortical Neurons were induced as described 
elsewhere (Y. Zhang et al., 2013) and maintained with neurobasal medium fully 
complemented and conditioned overnight on mouse astrocytes, or with neurobasal 
plus (Thermoscientific). LCL were grown in RPMI 1640, FBS 15%, HEPES 1%, L-
Glutamine 1%, Penicillin-Streptomycin 1%. All samples were tested for mycoplasma.  
Reprogramming into iPSCs 
The six fibroblasts samples: KAB_1, KAB_4, KAB_5, CTL_1, CTL_4, and CTL_5 
were reprogrammed into iPSC using a non-integrative method (Yoshioka et al., 
2013) based on the self-replicating Venezuelan Equine Encephalopathy (VEE) virus. 
The reprogramming was performed according to the manufacturer’s protocol 
(Simplicon™ RNA Reprogramming Technology, Millipore). VEE replicon presence 
removal was evaluated by RT-qPCR using already primers already published 
(Yoshioka et al., 2013). The fibroblast samples: KAB_3, KAB_7, GADEVS samples 
and control LCL were reprogrammed using Sendai virus according to following the 
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manufacturer’s protocol (CytoTune™-iPS 2.0 Sendai Reprogramming Kit, 
ThermoFisher Scientific). 
iPSCs Differentiation into NCSC and Cortical Neurons 
iPSCs were differentiated into NCSC using a published protocol (Menendez et al., 
2013). NCSC purity was assessed by FACS analysis using antibodies against NK-1 
and NGFR as previously described (Adamo et al., 2015).  
iPSCs Differentiation into Cortical Neurons 
iPSCs were engineered using a ePiggyBac (ePB) transposon. iPSCs were 
electroporated with the Neon system (ThermoFisher) with the following 
parameters: 1200V, 30 ms, 1 pulse using 0,5 µg of an helper plasmid expressing a 
transposase and 4,5 µg of donor plasmid with a transposable element with the 
following genetic configuration: hUbC promoter - rtTA  - T2A – BsdR -TRE – Ngn2 
– P2A – EGFP – T2A – PuroR as represented in Figure 10 to allow the selection of 
by administration of blasticidin 5µg/mL. Neuronal differentiation was driven by 
doxycycline administration followed by Ngn2 expression, differentiation and 
maturation were performed as already described (Zhang et al., 2013). Stainings on 
neurons were performed using nitric acid treated coverslips coated overnight with 
poly-L-Lysine. 
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Figure 10 Schematic represenation of Ngn2 ePB donor plasmid 
Immuno-Fluorescence Stainings 
Immunofluorescence stainings were performed on living cells using the TRA-1-60 
live cell staining, DyLight 488 conjugated( Stemgent, 09-0068). Stainings on fixed 
cells were performed washing samples with cold PBS. Cells were treated for 10 
minutes with  4% Paraformaldehyde/4% sucrose, washed with PBS, and 
permeabilized with Triton X-100 diluted in PBS. A blocking of 1 hour was performed 
in serum matched with the specie of the secondary antibody. After washes with PBS, 
samples were incubated 2 hours at room temperature or overnight at 4°C with the 
primary antibody diluted in blocking buffer. Samples washed with PBS to remove 
primary antibodies and incubated with secondary antibodies for 1 hour at room 
temperature. Secondary antibodies were removed by washing with PBS. Afterward, 
DAPI was given for 5 minutes, removed with PBS, and samples were finally mounted 
on coverslides with Moviol mounting medium. Stainings were performed using 
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Nanog (Everest Biotech, EB06860), Oct3/4 (Santacruz, sc-9081), TUJ1 
(Covance, MMS-435P), MAP2B (BD Biosciences, 610460), VGLUT1 (Synaptic 
System, 135 303). 
Protein extraction and immunoblotting 
Protein extraction was performed using RIPA buffer (150 mM NaCl, 1.0% NP-40, 
0.5% sodium deoxycholate, Protease inhibitor cocktail (Sigma), 0.1% SDS and 50 
mM Tris, pH 8.0) to lysate cells. Lysis was followed by sonication using the 
Bioruptor Sonication System (UCD200) for three cycles of 30s at high power with 
30s pauses and centrifuged at 13,000g for 15 min. Protein quantification was 
performed with Bradford protein assay (Bio-Rad). For protein electrophoresis 20–
40 μg of protein extracts were loaded on home-made 10% SDS-PAGE gels. Transfers 
were performed with a tension of 120V for 1 hour onto nitrocellulose membranes 
and blocked in TBS-T 0.2% (50 mM Tris, pH 7.5, 150 mM NaCl and 0.2% Tween-
20) and 5% milk. Primary and secondary antibodies were diluted in TBS-T 0.2%,  
5% milk. Odyssey Infrared Imaging System (LI-COR Biosciences) was used to 
acquire images. Densitometry was performed using ImageJ software. The secondary 
antibodies were a α-rabbit IRdye680LT or a α-mouse IRdye800LT (LI-COR 
Biosciences). 
RNA-seq transcriptome analysis 
RNA samples were extracted using the RNeasy Micro Plus kit (Qiagen) according to 
the manufacturer's protocol. RLT buffer containing β-mercaptoethanol was directly 
added to samples. RNA Concentration and purity was evaluated by the NanoDrop 
(NanoDrop Technologies). Before RNA-seq library construction, RNA integrity was 
assessed by 2100 Bioanalyzer (Agilent Technologies). Only samples with RIN > 9 
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were used for library preparation. Prior library preparation ERCC spike-ins 
(ThermoFisher Scientific) were used to facilitate data normalization. RNA-seq 
libraries were prepared following manufacter protocols for Truseq-stranded 
RiboZero depletion (Illumina). Libraries were sequenced using a HiSeq2000 
(Illumina) at a depth of 30 million reads, paired-end, 50bp sequencing. RNA-seq 
analysis was performed directly from the reads using Salmon 6.1(Patro et al., 2015), 
which has been showed to be excellent in tracking relative gene expression 
differences (Germain et al., 2016), using hg38 and the Refseq annotation 
complemented with the sequences of the ERCC spike-ins.  
ChIP-seq epigenomic analysis 
Chromatin immunoprecipitations were performed as previously described  (Frank 
et al., 2001) with some modification. Cross-linking was performed using 
formaldehyde 1% in PBS. Glycine was added to the final concentration 125 mM to 
quench formaldehyde. Cells were re-suspended using ChIP SDS buffer (0.5% SDS, 
5 mM EDTA, NaCl 100mM and 50 mM Tris-HCl at pH 8.1). Pellets were collected 
at 400g for 30 min and resuspended in IP buffer (0.5% SDS, 5 mM EDTA, NaCl 
100mM and 50 mM Tris-HCl at pH 8.6, Triton X-100 1,5%). Cells were sonicated to 
obtain chromatin size of 300 bp DNA fragments, using the Branson digital sonifier 
(Emerson Industrial Automation). Chromatin for ChIP was quantified using 
Bradford protein assay (Bio-Rad) or normalized on cell number. 
For each chromatin modification, IPs were performed using 100 µg of chromatin. 
Antibody used were: Ab8580 (H3K4me3), Ab8895 (H3K4me31), Ab4729 
(H3K27Ac), 9733B (H3K27me3), sc-1703 and sc-281 (YY1). Chromatin was 
incubated overnight with 2 µg of antibody at 4°C.  Protein G - Sepharose 4B (Thermo 
Fisher) were incubated with chromatin and antibodies mix for 4 hours at 4°C. 
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Washes were conducted by using low and high salt buffers (1% Triton X-100, 0.1% 
SDS, 150mM or 500mM NaCl , 2mM EDTA, 20 mM Tris-HCl ph8). Decross-linking 
was performed at 65°C for 3 hours. DNA was collected with QIAquick PCR 
Purification Kit (Qiagen). Libraries were prepared as already described (Blecher-
Gonen et al., 2013) with adaptations for the automated system Biomek FX.  
ChIP-seq reads were trimmed using scythe 0.981 
(min 4 nucleotides) before being aligned to the hg38 genome using Bowtie 1.0 (-v 2 
-m 1), peaks were called using MACS 2.0.9 with default settings (except for H3K27ac 
and H3K27me3 for which the 'broad' option was enabled).  
Differential expression analyses  
Differential expression analyses (DEA) were performed with EdgeR (Robinson et 
al., 2010) with the parameter “estimateGLMRobustDisp”, taking in account 
genotypes, sex, family (when possible), and batches when present. Gene ontology 
analysis were performed by in-house tool, Ingenuity pathway analysis (IPA, Qiagen) 
and the online tool webgestalt10, which permits to load a custom universe of genes 
as background (taking in account the expressed genes for each specific cell type) 
selecting Over-Representation Analysis. 
Micro electrode arrays recordings and Neuronal network 
analysis  
Eight iPSCs (4 lines from Kabuki patients, 3 lines reprogrammed from half-matched 
and one unmatched healthy subjects) were differentiated into upper-layer excitatory 
cortical neurons as described above. The derived neurons were plated onto MEAs or 
                                                   
10 http://www.webgestalt.org 
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glass coverslips pre-coated with adhesion promoting factors (Poly-L-Ornithine 50 
µg/mL and Laminin 20 µg/mL) at a final density of 100 and 600 cells/mm2 
respectively.  After two days, rat astrocytes were added in the culture at the same 
density. Recordings of the spontaneous activity of hiPSCs-derived neuronal 
networks were performed during the 5th week in vitro. Recordings were performed 
using the 24-well MEA system (Multichannel Systems, MCS GmbH, Reutlingen, 
Germany). Spontaneous electrophysiological activity of hiPSC-derived neuronal 
network grown on MEAs was recorded for 20 min. The signal was sampled at 10 
KHz, filtered with a high-pass filter (i.e. butterworth, 100 Hz cutoff frequency) and 
the noise threshold was set at ±4.5 standard deviations. During the recording, the 
temperature was maintained constant at 37 °C, and the evaporation and pH changes 
of the medium was prevented by inflating a constant, slow flow of humidified gas 
(5% CO2, 20% O2, 75% N2) onto the MEA. Data analysis was performed off-line by 
using a custom software package named SPYCODE (Bologna et al., 2010) developed 
in MATLAB (The Mathworks, Natick, MA, USA). Cells plated on coverslips were 
transfected with a pCAG-dsRED plasmids 7 days after plating. After 23 days in vitro, 
cells were fixed and mounted for imaging. Neurons were imaged using an Axio 
Imager Z1with 568nm laser light and  Axiocam 506 mono. Neurons were digitally 
reconstructed using Neurolucida 360 software (MBF–Bioscience, Williston, ND, 
USA).  
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RESULTS 
Kabuki syndrome modelling 
Cohort of patients and fibroblasts characterization  
Thanks to the collaboration with the Telethon biobank we obtained Fibroblasts 
samples of seven KS patients and five matched un-affected relatives. As depicted in 
Figure 11 all individuals carry indel or nonsense mutations that eventually lead to a 
premature termination codon (PTC), which is predicted to activate nonsense 
mediated decay (NMD). 
 
 
Figure 11 Schematic represenation of KTM2D exons with mutations position for availavle KS individuals. RThe 
number in the sample name identifies the family. Controls individuals are half-matched, sex-matched 
unaffected relatives. 
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Heterozygous mutations of KMT2D do not affect bluk H3K4 methylation 
deposition 
Even though the KS individuals carry a heterozygous mutation on KMT2D, in 
fibroblasts samples the bulk level of H3K4 post-translational modification was not 
affected, as shown in  Figure 12. 
 
Figure 12 heterozygous KMT2D mutations do not affect bulk H3K4 post-translational methylations. Western 
Blotting for H3K4 modification in fibroblasts lysates.  
 
Molecular characterization of KS primary fibroblast samples 
Transcriptome analysis was performed on the whole cohort of primary fibroblast 
samples. DEA identified 189 Differentially Expressed Genes (DEGs) as shown in 
Figure 13. Although the number of DEGs is not high, it is possible to identify 
statistically significant enrichment that can be related with the clinical phenotype, 
as depicted in Figure 14.  
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Figure 13 Transcriptional characterization of KS primary fibroblasts and half matched samples. A: 
Differentially Expressed Genes (DEGs) detected by EdgeR paired analysis. Conditions: Red: Kabuki; Blue:  B: 
Volcano Plot: gene expression distribution 
 
 
Figure 14 Goseq enrichment analysis in fibroblasts RNA-seq data 
Given the enzymatic activity of KMT2D the genomic distribution of H3K4me1 was 
analysed. ChIP-seq result for this histone modification identified 7455 (Figure 15) 
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differentially methylated regions (DMRs) between patients and control. Moreover, 
Principal Component Analysis (PCA) highlights a clear clustering separation 
between patients and controls (Figure 15B). Although the bulk H3K4me1 does not 
change, H3K4me1 distribution is affected at specific loci in KS.  
 
Figure 15 Genome wide distribution of H3K4me1 in primary fibroblasts of KS individuals and matched 
controls. A: Differentially  methylated regions detected using EdgeR paired analysis. Conditions: Red: 
Kabuki; Blue: Controls. 
 
According to previous research (Lee et al., 2013a) that describe KMT2D with a key 
role in enhancer regulation, the peak distribution is mainly lost at distal intergenic 
regions (Figure 15C), while regions proximal to gene promoters are less affected. To 
further valorise our H3K4me1 ChIP-seq we crossed it with the Roadmap 
Epigenomics public data (Kundaje et al., 2015) using dermal fibroblast histone 
modification data (Figure 6). Here we can validate that KS have a defect in H3K4me1 
in regions normally marked with this histone modification in Roadmap epigenomics 
datasets. Moreover, regions marked by H3K27me3, in Roadmap epigenomics 
45 
 
datasets, are aberrantly marked by H3K4me1 in KS primary fibroblasts. This 
observation might be caused by an aberrant compensation of the other COMPASS 
complexes. To validate this observation, we performed H3K27me3 ChIP-seq in 
fibroblast samples, the current result remains inconclusive. Therefore, this data 
needs further analysis.  
 
Figure 16 H3K4me1 ChIP-seq data overlap with Roadmap epigenomics data. Numbers among brackets: total 
numbers of peaks.  Numbers in the boxes: overlapping peaks; Colors:  Z-score of ratio between columns and 
rows. Columns: genomic regions of H3K4me1 fibroblast ChIP-seq in set of different stringency 
 
Generation of Kabuki syndrome iPSCs  
To model the pathogenesis and the impact of KMT2D in non accessible tissues, 
starting from 3 patients and their matched controls we generated iPSCs with a non-
integrative self-replicating mRNA (Yoshioka et al., 2013) that contains GLIS1, a 
maternal factor highly expressed only in unfertilized egg and one-cell stage embryos, 
instead c-myc, and was shown to achieve superior reprogramming quality in terms 
of ES-cell-like colonies number and survival of chimaeric mice (Maekawa et al., 
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2011). 2 additional samples that were refractory to the reprogramming with this 
method were reprogrammed using the Sendai virus, a well-established 
reprogramming platform (Sochacki et al., 2016) that permits to reprogram with the 
classical OKSM factor with a single infection. First, iPSCs were characterized by 
immunofluorescence stainings for pluripotency defining markers NANOG, OCT4, 
TRA-1-60 (Figure 17). 
 
Figure 17 Representative staining for pluripotency defining markers in KS iPSCs. A: Anti TRA-1-60 4X, live 
staining; B: Phase-contrast; C: Anti NANOG 20X; D: DAPI 20X; E: OCT4 20X 
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Figure 18 iPSCs samples reprogrammed with self-replicating RNA method are negative for the VEE construct. 
A: TBP qPCRgel is positive only for iPSCs and fibroblasts;B: VEE nsP2 qPCR gel is negative for iPSCs and 
fibroblasts; C: TBP qPCR is positive only for iPSCs and fibroblasts, purple and close samples: positive control 
of VEE mRNA, water, negative for RT, no cDNA in reaction  D: VEE nsP2 qPCR is negative for iPSCs and 
fibroblasts, purple: positive control of VEE mRNA Melt curves of iPSCs are equivalent to negative RT, water, 
no cDNA in reaction, and fibroblast sample. 
Then, to verify the complete depletion of the self-replicating mRNA from the 
reprogrammed colonies, as a consequence of the removal of B18R from the 
reprogramming medium (which was added to suppress the innate immune system), 
qPCR with primers designed to detect the construct was performed on all samples. 
iPSCs and a fibroblast sample were positive for TBP and completely negative for the 
self-replicating mRNA compared with a positive control   (Figure 18).  
iPSCs obtained with self-replicating mRNA were profiled with RNA-seq to assess 
both the impact of KMT2D mutation at the pluripotent stage.  As depicted in Figure 
19,  KMT2D heterozygous mutations impact the pluripotency stage only marginally. 
With 0,05 FDR 295 DEGs were identified; 907 with an FDR of 0,1. Although the 
number of DEGs were comparable to the ones detected in fibroblasts, no Gene 
Ontology enrichment were identified. Indeed,  clones of each individual, family and 
condition cluster together in unsupervised clustering (Figure 20), which shows a 
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high homogeneity among clones, indicating that at the pluripotency stage the 
genetic background overrides the differences imputed to KMT2D mutations. To 
assess whether the mutation could impact the enhancer activation status in 
pluripotency, iPSCs generated with the self-replicating mRNA were analyzed for 
H3K4me1 and H3K27Ac ChIP-seq. Consistent with the transcriptomic analysis, also 
the ChIP-seq results show an alteration at very few loci and PCA analysis are not 
able to detect any clear separation between KS and control samples both for 
H3K4me1 and H3K27Ac (Figure 21 and Figure 22). 
 
Figure 19 Transcriptome analysis of KS iPSCs and matched controls reprogrammed with self-replicating 
mRNA.  KMT2D mutations do not dramatically alter the transcriptome in pluripotency Scalebar: Log norm 
gene counts FDR: 0,05 
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Figure 20 Unsupervised clustering of iPSC transcriptome shows high correlation among clones of each patient 
and individuals of each family. Color code: Pearson correlation of z-scores across all samples.  
 
Figure 21 H3K4me1 in KS iPSCs reprogrammed with self replicating mRNA. A: PCA analysis; B: Differentially 
methylated regions 
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Figure 22 H3K27Ac in KS and half-mathced controls reprogrammed with self-replicating mRNA. H3K27Ac 
ChIP-seq in iPSCs A: PCA analysis; B: Differentially methylated regions 
It is important to underscore that at the pluripotent stage RPKM values for KMT2D 
do not show a statistical difference between controls and KS (Figure 23).  To increase 
the sample number size, using the Sendai Virus, two additional KS samples were 
reprogrammed into iPSCs. The following table summarizes the complete cohort of 
obtained KS iPSCs.  
Figure 23 KMT2D expression values in iPSCs. Values in the barplot: RPKM 
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Table 1 iPSCs clones. Letters following family number identify iPSCs clones 
Clone names Reprogramming method 
CTL_1A Self-replicating mRNA VEE 
CTL_1B Self-replicating mRNA VEE 
CTL_1C Self-replicating mRNA VEE 
CTL_4A Self-replicating mRNA VEE 
CTL_4B Self-replicating mRNA VEE 
CTL_4C Self-replicating mRNA VEE 
CTL_5A Self-replicating mRNA VEE 
CTL_5C Self-replicating mRNA VEE 
KAB_1A Self-replicating mRNA VEE 
KAB_3A Sendai Virus 
KAB_3B Sendai Virus 
KAB_3C Sendai Virus 
KAB_4A Self-replicating mRNA VEE 
KAB_4B Self-replicating mRNA VEE 
KAB_4C Self-replicating mRNA VEE 
KAB_5A Self-replicating mRNA VEE 
KAB_5B Self-replicating mRNA VEE 
KAB_5C Self-replicating mRNA VEE 
KAB_7A Sendai Virus 
KAB_7B Sendai Virus 
KAB_7C Sendai Virus 
KAB_7D Sendai Virus 
KAB_7E Sendai Virus 
KAB_7F Sendai Virus 
KAB_7G Sendai Virus 
 
Differentiation of KS iPSCs into disease-relevant cell types 
For each individual, several iPSCs clones have been selected for expansion and used 
to analyze the pluripotent stage. To decide the number of iPSC clones to be 
differentiated in disease-relevant cell types we took in account several factors. From 
RNA-seq and ChIP-seq data, each clone has been found to be homogenous with the 
other iPSCs clones from the same individual. The major source of variability was 
identified to be the familial genetic background, as each clone of individuals of the 
same families segregated together. Moreover, genetic variation within iPSC clones,  
that was initially thought to be induced by the reprogramming process has been 
demonstrated to arise from somatic chimerism already existing in the parental cell 
from which the iPSC clone arose (Abyzov et al., 2012; Young et al., 2012). Also, it 
has been described that the primary source of variability among iPSCs clones 
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coming from different subjects arises from inter-individual genetic differences 
(Kilpinen et al., 2017).  Accordingly, given the genetic heterogeneity between 
individuals, to obtain a robust experimental design able to flatten differences 
coming from such genetic backgrounds, and to outstand the variability driven by 
shared genetic lesions, recent in silico analysis suggested to increase the sample 
cohort by including multiple biological replicates (defined as individuals with 
unrelated genetic background) rather than increasing the number of clones of fewer 
subjects: a practice that increases the probability of identifying false positives as 
bona fide differentially expressed genes (Germain and Testa, 2017). Indeed, 
permutation analysis showed that the use of multiple clones per individual can be 
detrimental for transcriptomic studies, while the use of a single clone and multiple 
individuals benefit the specificity and sensitivity (Germain and Testa, 2017). 
Therefore, given the fact that in this project we obtained a number of individuals’ 
iPSCs compatible with the scenario that permits to identify the highest number of 
bona fide DEGs, keeping low the number of false positives, we decided to 
differentiate only one clone from each individual into disease-relevant cell types.  
Differentiation in cranial neural crest stem cells 
 
NCSCs are involved in the development of multiple tissues, organs, and systems 
affected in KS, such as the immune system, the atrial septa, the gastrointestinal 
tract, craniofacial structures, and many others (see Chapter “ The Neural Crest Stem 
Cells”). To study how KMT2D heterozygosity is responsible for craniofacial 
dysmorphisms, we decided to differentiate iPSCs to cranial NCSC using a two weeks 
protocol (Menendez et al., 2013) already established in the laboratory (Adamo et al., 
2015). The purity of the differentiation was assessed by FACS analyses for surface 
markers NHK-1 and NGFR (Menendez et al., 2013), as depicted in Figure 24.  
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Figure 24 FACS analysis show positivity for NGFR and NHK-1  
 
Transcriptional characterization of KS neural crest stem cells  
NCSCs were subjected to transcriptome analysis and genome-wide characterization 
of H3K4me1 and H3K27Ac. PCA of transcriptome does not show any clear 
separation between KS and controls ( Figure 25). 
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Figure 25 PCA of KS NCSC and matched controls 
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With an FDR threshold of 0,05 only 42 DEGs were identified (Figure 26). 
 
Figure 26 RNAseq of KS NCSCs and controls. FDR: 0,05. Scale log norm gene counts. Clustering: Pearson 
distance 
 
Given the fact that two KS do not have an half matched healthy control to be 
matched with, the DEA was repeated without keeping in consideration the family 
covariate. In this case, the DEGs with an FDR of 0,05 were reduced to 31 (Figure 
27). Lowering the FDR threshold to 0,1 and intersecting the between the two 
analyses, the following genes were overlapping: 'GDA', 'ITGA10', 'PCDHB5', 'MX2', 
'PCDHGB4', 'BLOC1S5', 'COL9A3', 'AP1S2', 'PCDHGB6', 'ANO5', 'FRAS1', 'TNS2', 
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'FGF2', 'KBTBD11', 'ABCG1'. These genes are enriched for the biological process “cell 
adhesion” with an FDR of 4.18E-05.  
 
Figure 27 RNAseq of KS NCSCs and controls. FDR: 0,05. Scale log norm gene counts. Family was not included 
as covariate. Clustering: Pearson distance  
The expression level of KMT2D, evaluated as RPKM, shows a reduction trend in KS 
when compared to the controls but it is not statistically significant (Figure 28). 
Worth of mention, in the analysis without the family as covariate, KDM6A has a 
logFC of 0,59, resulting overexpressed, with a P-value of 0,005, showing a 
potentially very relevant compensatory trend, despite the fact that its differential 
expression does not pass multiple test correction.  
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Figure 28 KMT2D RPKM in KS NCSC and controls 
By selecting DEGS with a pValue < 0,05 it is possible to find enrichment for 
biological processes relevant for neural crest and the KS clinical traits such as 
“cardiac septum morphogenesis”, “eyes morphogenesis”, “kidneys morphogenesis” 
, and “central nervous system development” (Figure 29).  
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Figure 29 biological processes enrichment for DEGS (pValue <0,05) in KS and control NCSCs 
 
H3K4me1 and H3K27Ac analysis of KS NCSCs  
Following H3K4me1 ChIP-seq analysis on KS NCSC and controls, a Kabuki sample 
was excluded given the failure of immunoprecipitation (Figure 30).  By normalizing 
on library size 32 differentially methylated regions (DMR) between controls and KS 
samples were identified, with an FDR of 0,1. To identify the putative target genes of 
these DMRs, given the lack of HiC dataset in human NCSC, this data was crossed 
with an internal set of presumptive enhancers, identified by high-throughput 
profiling of a large cohort of 32  NCSCs lines by means of both RNA-seq and ChIPseq 
experiments, thus generated by overlapping regions positive for H3K27Ac, 
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H3K4me1, excluding promoter regions (positive for H3K4me3), and choosing the 
closest expressed gene (without any distance limit). 
  
Figure 30 genomic density distribution of H3K4me1 in KS and controls NCSC. The red sample was excluded 
given the anomalous distribution  
 
By doing so, a subset of putative active enhancers with diminished  H3K4me1 signal 
was identified and crossed with the DEGs identified in NCSC. Without filtering for 
FDR, the genes NEDD4L, PEG3, PHTF2, SLC15A4, SLITRK1, TMEM132B, 
TMEM132C, TXNL1, UNC5D, WSCD2, and ZIM2 resulted to have a putative active 
enhancer with a reduction in H3K4me1. The function of these genes is summarized 
in the following table: 
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Table 2 genes with a reduction of H3K4me1 in putative enhancers in NCSC 
  protein class OMIM disease 
Phenotype MIM 
number 
NEDD4L E3 ubiquitin ligase 
Periventricular 
nodular 
heterotopia 7 617201 
PEG3 
KRAB box transcription 
factor 
 
Undifferentiated 
Embryonal 
Sarcoma Of The 
Liver and Glioma NA 
PHTF2 
homeodomain 
transcription factor NA NA 
SLC15A4 histidine transporter 
 Cri-Du-Chat 
Syndrome 123450 
SLITRK1 
receptor with neurite-
modulating activity 
Trichotillomania 
and Tourette 
syndrome 613229 and 137580 
TMEM132B transmembrane protein NA NA 
TMEM132C transmembrane protein NA NA 
TXNL1 redox activity 
Thymus 
Adenocarcinoma NA 
UNC5D Netrin Receptor  Anisometropia   
WSCD2 NA Porokeratosis NA 
ZIM2  
KRAB box transcription 
factor NA NA 
 
The same procedure was applied to H3K27Ac data. Quantitative analysis of 
H3K27Ac identified 11 regions differentially acetylated with FDR < 0,05. Increasing 
the DEGs FDR threshold to 0,1 and intersecting these differentially acetylated 
regions with our internal database, to identify regulated genes of these putative 
deregulated active enhancers, PAX8 and TMEM132C were identified.  Importantly, 
PAX8 is a transcription factor mutated in congenital hypothyroidism (OMIM: 
218700). 
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Structural and physiological characterization of upper layer cortical 
neurons obtained from KS iPSCs  
To probe the spontaneous electrophysiological activity and to characterize the 
neuronal network structure, upper layer cortical neurons were obtained by 
overexpressing Ngn2 (Y. Zhang et al., 2013) (hereafter referred to as iNeurons) from 
4 KS patients, 3 half-matched healthy controls, and one unmatched control. 
Immunofluorescence showed positivity for general neuronal markers MAP2, TUJ1 
(Figure 31), and for glutamatergic neurons VGLUT1 (Figure 32) already after 12 days 
after doxycycline administration.  
 
Figure 31 TUJ1 and MAP2 stainings of Ngn2 neurons. Day 12 after Dox induction. Confocal 63x magnification. 
Co-culture with astrocytes 
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Figure 32 VGLUT1 and MAP2 stainings of Ngn2 neurons. Day 12 after Dox induction. Confocal 63x 
magnification. Co-culture with astrocytes. 
 
At day 23 of differentiation iNeurons showed mature morphology and 
morphological parameters, such as number of primary dendrites, nodes, and 
primary endings, did not show any statistical difference between KS and control 
samples (Figure 33).  
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Figure 33 Structural analysis of neurons. a-b) Representative images of a) control and b) KS neurons 
transfected with dsRed (scale: 50 µm). Graphs c-e) showing the c) number of primary dendrites, d) nodes and 
e) dendritic endings in control (black, n=39) and Kabuki neurons (red, n=52) derived from hiPSCs (i.e. pooled 
results).  Graphs f-h) showing differences in f) number of primary dendrites, g) nodes and h) endings in 
neurons derived from 4 control (black, C1 n=5, C2 n=15, C3 n=5, C4 n=14) and 4 Kabuki (red, KS1 n=12, KS2  
n=13, KS3 n=14, KS4 n=13) hiPSCs lines. Data represent means ± SEM. Statistics: normality test, Kruskal-
Walis Test, post-hoc Bonferroni correction. 
From micro-electrode arrays (MEAs) analysis it is possible to record spontaneous 
spikes, burst, and network bursts, which are indicative of a mature organized 
neuronal network Figure 34.   
 
Figure 34 Schematic depiction of a MEA with 12 electrodes and definition of spike, burst and network burst. 
 
Already during the second week in vitro, which start is defined as the moment of 
plating on MEAs, the neurons derived from healthy subjects formed functionally 
active neuronal networks, showing spontaneous events (i.e. spike and burst, Figure 
34).  Late in development (i.e. fifth week in vitro) the neuronal network showed high 
level of spontaneous activity as well as regular network bursting pattern (i.e. 
synchronous events involving almost all channels of the MEAs, highlighted in grey 
in Figure 35A). Neurons derived from KS patients established spiking activity during 
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early network development as well as network burst involving most of the channels 
of the MEAs later in development (Figure 35B). During the fifth week in vitro, at the 
population level KS patient-derived neuronal networks exhibited a global level of 
activity that was slightly higher than controls (i.e. firing rate Figure 35C, p=0.049). 
The level of synchronous activity exhibited by KS-derived neuronal network was 
comparable to control ( Figure 35D, p=0.02), too. Although the level of both global 
and synchronous activity was only slightly impaired, the pattern of activity exhibited 
by KS patient-derived neuronal networks was very different compared to control 
condition. First, the percentage of random spike (i.e. events not organized within a 
burst) was statistically lower in KS-derived neuronal compared to control ( Figure 
35E, p<0.00025). Furthermore, the network burst appeared with longer durations 
compared to controls ( Figure 35F, p<0.00025). The interval occurring between two 
consecutive network bursts was also longer compared to control condition (i.e. inter 
burst interval,  Figure 35G, statistically different before Bonferroni correction). 
Finally, the pattern of synchronous activity (i.e. in terms of timing and organization) 
was impaired in KS-derived neuronal networks. In particular, KS patient-derived 
neuronal networks exhibited an irregular bursting pattern, as shown in the raster 
plots in  Figure 35A-B. Then, the organization of the burst involved in a synchronous 
event was different. In control condition, a network burst was composed but single 
burst appearing simultaneously in most of the channel (see raw data highlighted in 
black in  Figure 35A).  Instead, the network burst exhibited by KS-derived neuronal 
networks was composed by “mini-bursts” (i.e. 4 “mini-bursts”, see raw data 
highlighted in red in  Figure 35A and  Figure 35H). The results indicate that KS-
derived neuronal cultures showed an altered pattern of activity in excitatory 
neuronal networks.  
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Figure 35 Spontaneous electrophysiological activity of neuronal networks grown on MEAs. A) raw data of 
recordings from representative control; B) raw data of recordings from representative KS; C) mean firing 
rate; D) network burst rate; E) percentage of random spikes; F) network burst duration; G) inter-network 
burst interval; H) average number of mini-burst observed. 
 
Transcriptional characterization of upper layer cortical neurons obtained 
from KS iPSCs  
iNeurons at day 31 were subjected to RNA-seq to identify molecular dysfunction that 
could explain the phenotype observed by MEA analysis, which was not explained by 
the neuronal network architecture. First, to confirm neuronal identity of cortical 
neurons, the expression level of a panel of genes, representative of glutamatergic 
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neurons, glycinergic and GABA-ergic interneurons, dopaminergic, and cholinergic 
neurons,  housekeeping genes, pluripotency genes, several markers specific of 
cortical layers I-VI, markers of neurogenesis, post-mitotic neurons, glia, and 
expression for chromatin remodelers relevant for neurodevelopmental syndromes, 
was investigated in this iNeuron cohort as depicted in Figure 36. Expression levels 
of selected markers, listed in Table 3, indicate neuronal identity of upper layer 
cortical excitatory neurons.  
67 
 
 
Figure 36 Expression of genes used to check the identity of neurons at day 30 of differentiation. Blue genes 
appear as not expressed and are filtered out during differential expression analysis.  
 
Table 3 Gene selected to assess transcriptional identity of Ngn2 neurons 
Function gene OMIM 
Cortical layers 
Layer I RELN 600514 
Layer II-IV POU3F2 600494 
Layer II-III 
CUX1 116896 
RASGRF2 606614 
Upper Layer neuron generation 
CACNA1E 601013 
PRSS12 606709 
CARTPT 602606 
Layer IV PCDH20 614449 
Layer IV 
GRM4 604100 
CALB1 114050 
RORB 601972 
NECAB1 618130 
Layer V 
ETV1 600541 
SOX5 604975 
BCL11B (CTIP2) 606558 
LDB2 603450 
GRB14 601524 
SYT9 613528 
CRIM1 606189 
Layer VI 
TBR1 604616 
FOXP2 605317 
BCL11B (CTIP2) 606558 
NFIA 600727 
NOS1AP 605551 
ADRA2A 104210 
Neurogenesis 
Early in neuronal development 
NES 
600915 
NCAM2 602040 
MSI1 603328 
Neuronal precursor cells and 
immature neurons 
DCX 
300121 
Dendrite structures 
MAP2 157130 
MAP1B 157129 
Involved in neurogenesis, axon 
guidance, and maintenance 
TUBB3 (Tuj1) 
602661 
Axon formation ANK3 600465 
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Post-mitotic 
neurons 
 
RBFOX3 (NeuN) 
616999 
Post-synaptic 
marker 
Synaptic vesicle endocytosis SYP 
313475 
Glutamatergic 
neurons 
Vesicular glutamate transporters 
SLC17A6 (VGLUT2) 
607563 
SLC17A7 (VGLUT1) 
605208 
NMDA glutamate receptor GRIN1 138249 
Glutamatergic neurogenesis 
NEUROG2 (Ngn2) 606624 
PAX6 607108 
EOMES (TBR2) 604615 
Glycinergic and 
GABAergic neurons 
Glycinergic neurons 
SLC6A9 
601724 
SLC6A5 604159 
Gabaergic neurons 
GAD1 
605363 
GAD2 138275 
Transports both GABA and 
glycine into synaptic vesicles 
SLC32A1 
616440 
Dopaminergic 
neurons 
Differentiation and survival of 
midbrain dopaminergic neurons 
NEUROG2 
606624 
 DRD5 126453 
Cholinergic neurons  CHAT 118490 
Interneurons 
Cortical interneuron subclasses 
CALB1 
114050 
CALB2 114051 
Inhibitory axon terminals 
impinging upon hippocampal 
interneurons 
CNR1 
114610 
Cortical and hippocampal 
interneurons 
DLX1 
600029 
somatostatin-containing 
interneurons in stratum oriens 
alveus 
NPY 
162640 
striatal interneuron PVALB 168890 
neocortical interneurons HTR2A 182135 
Pluripotency and 
neuronal 
progenitors 
Pluripotency NANOG 
607937 
 LIN28A 611043 
 KLF4 602253 
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 GLIS1 610378 
 POU5F1 (OCT4) 164177 
Pluripotency and neural stem cells SOX2 184429 
Neuronal progenitors DIAPH3 614567 
Housekeeping genes 
highly expressed HK GAPDH 138400 
TUBB 191130 
lowly expressed HK TBP 600075 
Markers of 
oligodendrocytes 
and glia 
 
GFAP 137780 
OLIG1 606385 
Chromatin 
remodelers involved 
in ND 
 
KMT2D 
602113 
SMARCA4 603254 
ADNP 611386 
 
The male patient was excluded from the analysis given the low quality of the 
sequencing and possible cross-contamination during flow-cell preparation. 
Consequently, to have the cohort balanced for the gender, also the male half-
matched unaffected control has been excluded. Therefore, to increase the 
robustness of the Differential expression analysis (DEA), four independent control 
samples were included in the analysis. In this cell type, 1318 DEGs were identified 
(Figure 37), with an FDR of 0,05. These genes are enriched in categories that are 
strictly related to neuronal function (Figure 38) and to translation. Solute carriers 
and axonal morphogenesis genes appear to be deregulated. Consistent with the 
considerable transcriptional alteration, here KMT2D results more than halved 
(logFC -0,79, FDR: 0.0004853473). On the other hand, KDM6A here is significantly 
upregulated ( logFC: 0.9506504, FDR: 7.488772e-05). 
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Figure 37 DEGs of KS and controls cortical neurons at day 30. FDR: 0,05; Scale: log norm gene counts. 
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Figure 38 Gene Ontology for biological processes iNeurons DEGs. 
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To better understand transcriptional 
alteration in iNeurons, several tools for 
gene ontology analysis were adopted. 
Moreover, overexpressed and 
downregulated genes were also analyzed 
separately. By doing so, it is possible to see 
that overexpressed genes are enriched in 
categories related to translation initiation 
and to nonsense-mediated decay (Figure 
39), downregulated genes are specifically 
enriched for categories specific for 
neuronal function and signaling (Figure 
40).  
 
 
 
Figure 39 Enrichment results for biological processes in 
upregulated genes. Overrepresentation Enrichment 
Analysis using Webgestalt. Reference gene list: genes 
expressed in Ngn2 neurons.  
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Figure 40 Enrichment results for biological processes in downregulated genes. Overrepresentation 
Enrichment Analysis using Webgestalt. reference gene list: genes expressed in Ngn2 neurons 
Upregulation of translation and translation initiation was maintained also using the 
IPA tool (Qiagen).  Moreover, categories enriched for downregulated genes are again 
enriched for neuron activity for excitatory neurons  Figure 41.  
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Figure 41 IPA analysis of iNeurons DEGs (FDR 0,05). Colors were manually changed to fit color blind 
visualization. Yellow line: multiple-test correction significance 
Also, using IPA is possible to identify enrichment for disease in gene categories. By 
separating upregulated and downregulated genes, it is possible to uncover an 
interesting divergence between the two DEGs subsets. Upregulated genes are 
enriched for neuronal-related diseases, and tumor suppressor genes such as TP53, 
ATM, BAX, KLF10, and CDK1A (known as p21). On the other hand, downregulated 
genes are enriched for melanoma and gastrointestinal tumors, as showed in the 
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Table 4, in particular, RET, MET, WNT5A, INO80D, KRAS,   and RAS-related genes 
KSR2, RAB27B, RAB30, RAB31, RAB33A, RAB3B, RAB3IP, RAB6B, RABGAP1L, 
RAC3, RALGPS1, RAP1GAP2, RAPGEF2, RAPH1, RASSF5, and the transcription 
factors POU5F1B, POU4F1, SOX11, SOX4. Also, the tumor suppressor CHD5, which 
protects from neuroblastoma, is downregulated.  
Table 4 Top scoring "Disease and function" of IPA (Qiagen) analysis 
downregulated genes upregulated genes 
Diseases or Functions Annotation p-Value Diseases or Functions Annotation p-Value 
Cutaneous melanoma 1,29E-32 Cell death of osteosarcoma cells 2,81E-28 
Intestinal carcinoma 1,29E-32 Cell death of cancer cells 2,23E-18 
Large intestine adenocarcinoma 1,29E-32 Cell death of tumor cells 5,47E-18 
Large intestine carcinoma 1,42E-32 Translation 9,73E-18 
Gastrointestinal adenocarcinoma 9,96E-32 Translation of mRNA 3,79E-17 
Gastrointestinal carcinoma 2,06E-31 Translation of protein 8,38E-17 
Skin cancer 4,60E-31 Expression of mRNA 9,27E-16 
Gastrointestinal tumor 6,46E-31 Metabolism of protein 4,05E-15 
Intestinal tumor 6,57E-31 Synthesis of protein 2,29E-14 
Skin lesion 6,57E-31 Expression of protein 6,71E-14 
Skin tumor 7,30E-31 Cancer 7,20E-13 
Melanoma 8,84E-31 Solid tumor 1,52E-12 
Large intestine neoplasm 8,84E-31 Non-melanoma solid tumor 2,18E-12 
Liver carcinoma 1,08E-30 Tumorigenesis of tissue 2,88E-12 
Liver tumor 1,35E-30 Cell death 6,14E-12 
Intestinal cancer 6,37E-30 
Chemoresistant acute myeloid 
leukemia 6,84E-12 
Development of neurons 7,18E-30 Abdominal neoplasm 7,53E-12 
  
Given the high number of DEGs is possible to divide the genes into clusters 
according to their trend across samples. By applying k-means clustering, 6 clusters 
were identified. A master regulator analysis was performed in each cluster to 
identify putative regulators upstream of the DEGs composing each cluster. 
Interestingly, the cluster 3, included RBBP5 as upstream regulators of 27 genes of 
this cluster (FDR ~ 0,05). Among these 27 genes, there is an enrichment of RNA 
binding proteins (panther ORA, FDR: 2.35E-02), given by the five genes: NSA2, 
G3BP2, RPF1, ZC3H15, and ALKBH8. 
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Genome-wide H3K4me1 and H3K27ac analysis of iNeurons 
From the very same dishes used to collect RNA, chromatin was collected for ChIP-
seq analysis. There is no clear separation in genomic density distribution between 
control and KS samples (Figure 42) To link putative unregulated active enhancers 
to target genes, for this cell type it has been used the dataset for hippocampal 
neurons of the 4D project (Dekker et al., 2017). Of all expressed genes, the 
differential Hek4me1 regions are associated to 496 genes; the overlap with the DEGs 
(FDR 0,05) is of 47 genes, of which 30 are predicted to be bound at the enhancer by 
RBBP5, a partner of KMT2D (hypergeometric test p-Value: 2.42356254688917e-
81).  
 
Figure 42 genomic density of H3K4me1 in KS and control iNeurons, DIV 30. 
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Within the target genes of predicted enhancers to have H3K4me1 dysregulation, 
there is a biological process enrichment for biological categories (Figure 43) 
 
Figure 43 Biological processes treemap for genes of which putative enhancers have a dysregulation in 
H3K4me1 in Ks iNeurons at day 30. Values: FDR 0,05 
 
  upregulated genes 
downregulated 
genes 
In all 
expressed 
genes 
gain in H3K4me1 
29 
  640 
loss of H3K4me1  8 104 
total DEGs FDR 
0,5 565 753   
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After normalizing on library size, with the exception of one sample, KS samples show 
an increase of H3K27Ac (Figure 45
) in low-density 
regions, while showed a reduction in the regions with the highest density. The 
outlier KS sample also cluster together with controls in PCA, which with the 
exception of this sample, separated the samples on PC1 according to the genotype.  
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Figure 44 genomic density of H3K27Ac in KS and control iNeurons, DIV 30. Red: control samples; Blue: KS 
samples. 
 
Figure 45 PCA analysis of KS and controls H3K27Ac in iNeurons at day 30. Red: Control samples, Blue: KS 
samples 
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Given the distribution of density regions with gain and loss of H3K27Ac have been 
analyzed separately. Gene identified to be target genes of putative dysregulated 
enhancers were intersected with DEGs (FDR 0,1). The following table summarizes 
the results of the intersections: 
Table 5 Intersection with target regions of altered H3K27Ac with differentially expressed genes (FDR < 0,1) 
  upregulated genes 
downregulated 
genes 
In all 
expressed 
genes 
gain in H3K27Ac 221  1874 
loss of H3K27Ac  141 963 
total DEGs FDR 
0,1 877 1055  
 
Genes target with a loss of H3K27Ac are enriched for biological processes specific 
for neuronal function (Figure 46). Conversely, putative target genes with a gain of 
H3K27Ac are enriched in biological processes unrelated to neuronal physiology 
(Figure 47).  
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Figure 46 Biological processes treemap for genes of which putative enhancers have a loss in H3K27Ac. Values: 
FDR 
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Figure 47 Biological processes treemap for genes of which putative enhancers have a gain in H3K27Ac. Values: 
FDR 
 
The intersection between regions regulated by RBBP5 and DEGS (FDR < 0,1) with 
matched putative enhancer with H3K27ac alterations, with identified 98 genes with 
a loss of H3K27Ac and 140 genes with a gain in H3K27Ac in the enhancer regions. 
The genes with a loss of H3K27ac are enriched for biological processes specific for 
neuronal physiology (Figure 48). Genes with a gain of H3K27ac are enriched for 
“cargo loading into COPII-coated vesicle” ( FDR 3.3e-02).  
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Figure 48 Biological processes treemap for the intersection of genes regulated by RBBP5 with putative 
enhancers featuring a loss in H3K27Ac. Values: FDR 
On the other hand DEGs with a gain in H3K27Ac but not target of RBBP5 lose the 
enrichment for categories related to muscles and sarcoplasm (Figure 49). Also, 
DEGs with a loss in H3K27Ac but not target of RBBP5 completely lose any 
enrichment.  
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Figure 49 Biological processes enrichment for upregulated DEGs with a change in H3K27Ac in the enhancer 
region deployed by RBBP5 target genes 
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Gabriele-deVries syndrome from discovery to modeling 
Heterozygous YY1 mutations cause intellectual disability with 
facial dysmorphisms 
After the first identification of YY1 mutations in a trio exome-sequencing (Lisenka 
E. L. M. Vissers et al., 2010), in an international effort, we identified ten de novo 
mutations in a cohort of 14,969 individuals with an undiagnosed intellectual 
disability. The probability of observing this proportion of mutations in YY1 in a 
cohort of this size, after Bonferroni-adjustment, is p = 2.8 × 10−6 (Gabriele et al., 
2017).. These ten individuals, represented in Figure 50A, shared borderline to 
moderate intellectual disability and craniofacial dysmorphisms including facial 
asymmetry with a broad forehead, fullness of the upper eyelids, and an upper-lip 
indentation shaped like a Gingko leaf. In addition, were recurrently observed 
behavioral problems, movement abnormalities, intrauterine growth restriction, 
feeding problems, and eye abnormalities. 
Moreover, one or two individuals were also featuring abnormalities such as cleft 
palate, craniosynostosis, esophageal atresia, Epstein anomaly, and hydronephrosis. 
The genetic and phenotypic characterization of individuals featuring YY1 point 
mutations is summarized in Table 6. Mutations position is represented in Figure 
50B. 
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Figure 50 A) representation of GADEVS individuals sorted by age. B) Distribution of YY1 mutations. Pink: zinc 
finger domains; blue: frequency of non-pathogenic mutations in ExAC. Adapted from Gabriele M., et al. 2017. 
Moreover, we identified 13 individuals, with an overlapping phenotype of the 
individuals with YY1 point mutations, with genomic deletions of the size range from 
75Kb to 13Mb, which were completely deleting YY1, and of which half encompass 
also the maternal/paternal UPD(14) gene cluster (Gabriele et al., 2017). To study the 
impact of YY1 mutations, lymphoblastoid cell lines (LCLs) were derived from four 
heathy donors, two individuals with missense mutations located in the zinc finger 
domain (Individual 1 and 2 from now on referred as p.Asp380Tyr and p.Leu366Pro, 
respectively);  an individual with a nonsense mutation (individual 5 referred as 
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p.Lys179∗); and an individual with the complete YY1 deletion (referred as deletion), 
encompassing also the two genes SLC25A29 and SLC25A47. Sanger sequencing of 
YY1 cDNA with and without cycloheximide treatment of LCL confirmed NMD in 
p.Lys179∗, as shown in  Figure 51A. mRNA levels where halved in p.Lys179∗ and 
deletion, while  YY1 mRNA levels of individuals with missense variation were 
unaltered, as represented in Figure 51B. Protein abundance reflects mRNA levels ( 
Figure 51C).   
 
 
Figure 51 A) patient LCLs carrying mutation p.Lys179* show complete nonsense mediated decay. B) YY1 mRNA 
levels in LCL RNA-seq. C) YY1 protein levels normalized to β-tubulin. Adapted from Gabriele M., et al. 2017. 
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Table 6 individuals with de novo YY1 mutations  
   Individual 1 Individual 2 Individual 3 Individual 4 Individual 5 Individual 6 Individual 7 Individual 8 Individual 9 Individual 10 
M
u
ta
ti
o
n
 
cDNA 
change# 
c.1138G>T c.1097T>C c.1096C>G c.1030C>T c.535A>T c.1173delT c.1174_1176del c.385delG c.1015A>C c.958C>T 
Protein 
change* 
p.Asp380Tyr p.Leu366Pro p.(Leu366Val) p.(Gln344*) p.Lys179* p.(Asn391Lysfs*10) p.(Lys393del) p.(Asp129Ilefs*127) p.(Lys339Gln) p.(His320Tyr) 
Chromosome 
position∞ 
g.100743830G>T g.100743789T>C g.100743788C>G g.100742953C>T g.100706116A>T g.100743865del g.100743869-
110743871del 
g.100239629delG g.100742938A>C g.100742881C>T 
Inheritance de novo de novo de novo de novo de novo de novo de novo de novo de novo de novo 
PhyloP† 6.18 5.13 2.14 6.10 0.12 1.01 4.51 ‡ 2.87 4.97 6.26 
Mutation 
Taster 
damaging damaging damaging NA NA NA NA NA damaging damaging 
Polyphen-2 damaging damaging damaging NA NA NA NA NA damaging damaging 
Cohort size 10 500 500 350 100 5,500± 5,500± 6,709± 1,300 6,709± 
G
ro
w
th
 
 
Age 2y9m 15y10m 5y1m 39y 17y6m 7y10m 1y3m 35y 9y3m 1y5m 
Gender M M F F F M M F M F 
Birth weight 
(g; SD) 
2010 (-2.5) 2220 (-3) 2290 (-1.6) NA 2600 (-2) 2050 (-1.3) 2409 (-1.8) 3.5  3.83 3062 
Height (cm; 
SD) 
84 (-3) 170 (-1) 105.2 (-0.5) 153.5 (-1.5) 159 (+0.7) 124 (0) 77.2 (-0.8) 154.4 (-2.5) 125.5 (-1.5) 79.2 (-0.8) 
89 
 
Weight (kg; 
SD) 
NA 47.5 (-1.5) 12.5 (-2.1) 51 (-1) 65 (+0.7) 24.6 (0) 8.6 (-2.6) 52.8 (+0.3) 23 (-1.7) 9.1 (-1.5) 
HC (cm; SD) 48.5 (-1) 57 (+0.4) 50.5 (+0.6) 54 (-1.5) 56 (+0.7) 52.5 (0) 47.3 (0)  52.5 (-2) 50 cm (-1.3) 44.8 (-1.8) 
D
e
v
e
lo
p
m
e
n
t 
 
Motor 
development 
sitting 1y; 
walking2y9m 
 
walking 2y 
sitting 1y; 
walking4y8m 
mild delay 
 
 
walking 15m 
 
walking 3y 
sitting 1y 
 
 
walking 15m 
 
walking 6.5y 
sitting 5m; 
walking 22m 
Speech 
development 
first words 2y first words 2y mild delay mild delay first words 2y delayed, 2-3 word 
phrases 
first words 13m delay non-verbal first words 14m 
Intellectual 
disability 
moderate moderate mild mild mild/learning 
difficulties 
mild/moderate   mild (DQ 68) special education moderate/ severe NA 
N
e
u
ro
lo
g
ic
 
 
Hypotonia - - - + - - + - moderate  - 
Behavioral 
abnormality 
anxiety ASD  schizoaffective 
disorder 
ADHD - - - autism - 
Sleep 
disturbance 
- -  + + - - - - - 
Abnormality 
of movement 
- toe walking  tremor progressive 
dystonia 
waddling gait - progressive 
dystonia 
- - 
Brain MRI NA normal normal frontal gliosis, 
enlarged SA 
spaces 
normal delayed 
myelination,  
cortical dysplasia, 
diffuse white matter 
loss  
minimal 
prominence of 
the right lateral 
ventricle 
subcortical bifrontal 
white matter foci  
focal areas of 
encephalomalacia  
normal 
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F
a
c
ia
l 
d
y
s
m
o
rp
h
is
m
s
 
 
Facial 
asymmetry 
+ + + + - - mild mild + - 
Broad 
forehead  
+ + + + + + + + + + 
Simple 
posteriorly 
rotated ears  
+ + + + + + low-set simple  protruding 
Periorbital 
fullness 
+/- + + + + - - - suborbital fullness + 
Downslant - + + + - + - - + - 
Full nasal tip  + + + + + - + - + + 
Malar 
flattening 
+ + + + - + - + + + 
Indentation 
upper lip  
+ + + + - - + - - - 
Thick lower 
lip 
+ + mild + + + - - + + 
Pointed chin + + + - - + - - - - 
Other telecanthus  -   epiblepharon, 
high palate 
  Pierre-Robin 
sequence with CP 
 -   micrognathia, 
ptosis, sparse 
eyebrows 
dolichocephaly, 
hypotonic facies, 
frontal upsweep 
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O
th
e
r 
Extremities - patella luxations, 
finger joint laxity 
long fingers finger joint laxity, 
Sydney line, 
sandal gap 
hemihypotrophy 
distal left leg 
laterally deviated 
halluces 
-  distal 
arthrogryposis  
- 
Feeding 
problems 
+ + + (G-tube till 
2y5m) 
- + + (G-tube) + (G-tube) difficulty with 
chewing and 
swallowing 
consistently 
underweight  
+ 
Recurrent 
infections 
- + - - - - - - - - 
Eye 
abnormalities 
- strabismus - strabismus hypermetropia - strabismus - mild astigmatism strabismus 
Renal 
abnormalities 
HN HN, UPJ stenosis  - - - - - NA NA 
Cardiac 
abnormalities 
- -  - - ebstein’s anomaly PFO, small 
aorto-
pulmonary 
collateral 
 - - 
Legend: +, present; −, absent; +/−, minor; ADHD, attention deficit hyperactivity disorder; ASD, autism spectrum disorder; CP, cleft palate; 
DQ, developmental quotient; GH, growth hormone; G-tube, gastrostomy tube; HC, head circumference; HN, hydronephrosis; NA, not 
available; NK, not known; PFO, patent foramen ovale; SA, subarachnoid; TE, trachea-oesophageal; and UPJ, ureteropelvic junction. 
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YY1 deletions, nonsense or missense mutations affect YY1 
chromatin binding in TSS proximal and distal regions 
To test how YY1 missense mutations in the zinc finger domains and YY1 halved 
dosage could impact genomic localization, ChIP-seq was performed employing two 
independent antibodies, recognizing both the NTD and the CTD fragments of YY1. 
ChIP-seq results, represented in Figure 52, show overlap of the peak calling and a 
high Pearson correlation of fold enrichments over input in the union of enriched 
regions (>0.93). Peaks lost or retained are consisted across samples, irrespectively 
of the mutation. This underscore that both deletion, nonsense, and missense 
mutations reduce in the same measure YY1 capability of binding chromatin.  The 
read density (left panel Figure 16A) defined high-occupancy peaks, which were 
retained both in controls and in mutated individuals’ LCLs. Regions with a minor 
read density over the input were preferentially lost in mutants. The sample 
p.Asp380Tyr only shows higher number of peaks retained than the other samples 
due to its high coverage.  
Distribution of conserved YY1 peaks (Figure 52B) showed preferential genome 
occupancy (>77%) in regions close to promoters, defined as regions close less than 
1 kb upstream of the transcription start sites (TSSs). Gene ontology of these TSS 
YY1-bound genes revealed and enrichment in genes regulating transcription, mRNA 
processing, and translation Figure 52C). Regions with reduced YY1 binding are 
enriched in distal intergenic regions (Figure 52B).  
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Figure 52 YY1 ChIP-seq with double antibody. Horizontal lines represent peaks; white: undetectable YY1 signal; 
YY1 expression level addressed by RNA-seq; TPM: transcripts per million; FC: fold change in relation to the 
control samples. B) Distribution of conserved and “lost” YY1 peaks across genomic features. C) Gene Ontology 
(GO) enrichments of the YY1-bound TSS.  Adapted from Gabriele M., et al. 2017. 
 
YY1 Haploinsufficiency leads to differential expression of only a 
minority of its targets 
To estimate the impact of YY1-binding gene occupancy loss on gene expression, 
RNAseq was performed on YY1 mutated LCL individuals and including an 
additional control. Principal component analysis of these transcriptome shows a 
clear separation between controls and mutated sample across component 2 (Figure 
53A). The source of variability responsible for principal component 1 was not 
identified with any biological or technical factor probed (sex, age, coverage, 
sequencing lane, RNA extraction efficiency, or proportion of ribosomal or Epstein-
Barr virus RNA). Following differential expression analysis 152 DEGs were 
identified (Figure 53B). In this dataset, genes related to chromatin silencing were 
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significantly enriched with genes related to chromatin silencing (p ∼ 9 × 10−10). 
Figure 53C shows DEGs directly bound by YY1, which are about 21% of DEGs. Of all 
the YY1-bound genes, only <1% are differentially expressed.   
 
Figure 
53 
Impact 
of the 
YY1 
Mutation on transcription. A) PCA of LCLs’ RNA-seq.). B) Representation of differentially expressed genes in 
Volcano plot: brown dots represent genes which are directly bound by YY1. C) Heatmap of Z.-score of YY1-
bound DEGs and YY1 binding pattern. Adapted from Gabriele et. Al, 2017.  
 
To reduce technical variability and improve the robustness, RNA was extracted 
again from the same independently cultured LCLs samples, and including data from 
73 apparently healthy individuals LCLs transcriptional profiles available in the 
HapMap database (Montgomery et al., 2010). A large number of permutation 
analysis was performed to identify genes variable in healthy individuals, to find 
genes which expression was associated with YY1 expression levels, and to identify 
high-confidence DEGs between proband and controls (Gabriele et al., 2017). The set 
of genes associated with YY1 levels is composed of 6,687 genes, of which 2248 are 
directly bound by YY1. This set of genes is enriched in categories relevant for 
translation and transcription control, as well as wnt canonical pathway (Figure 54A 
and Figure 54B). Differentially expressed genes coming from this analysis are 
enriched in categories relevant for the disease such as synapse organization and 
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cardiac function (Figure 54C). Moreover, a subset of high-confidence DEGs 
composed of 50 genes, present in both analyses, was identified (Figure 54D). 
 
Figure 54 A) GO enrichments of the YY1-bound genes that show significant association with YY1 expression 
levels across HapMap LCLs data.  B) Overlap between YY1-bound and YY1-associated genes, and differentially 
expressed genes. C) GO enrichment for all differentially expressed genes. D) High-confidence DEGs (left) with 
YY1 bindings at their TSS (right).  
 
Regardless of the low overlap between DEGs and YY1-bound genes, DEGs had a 
greater decrease in YY1 binding in comparison to genes without a statistically 
significant difference in expression (p ∼ 1 × 10−4). A large overlap between the two 
distributions (Figure 55) suggests that the presence of binding partners is likely to 
distinguish YY1-dosage-dependent, transcriptionally affected genes in any given 
cellular state. 
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Figure 55 Distribution of YY1 binding foldchanges at the TSS of DEGs and not significantly DEGs. CPM: Counts 
per Million reads mapped 
 
YY1 Haploinsufficiency Is Associated with Widespread Loss of 
H3K27 Acetylation 
Since it is known from previous literature that YY1 interacts with several histone 
modifiers, especially lysine acetylases and deacetylases, such as HDAC1, HDAC2, 
p300, and CBP, and most DEGs are downregulated, the impact of YY1 
haploinsufficiency on H3K27Ac was evaluated by ChIP-seq. The distribution of 
H3K27Ac separates probands apart from controls (Figure 56A). Given the fact that 
different normalization methods may lead to different interpretation, H3K27ac data 
were analyzes with the most conservative analysis, focusing on genomic sites that 
were showing reduced H3K27Ac even under the assumption of no difference in the 
global distribution. This analysis potentially underestimates regions with H3K27Ac 
loss, but the possibility that spurious regions will be identified as artifacts of 
normalization is excluded (Gabriele et al., 2017). As a result of this analysis, 39% of 
YY1-bound DEGs lose H3K27Ac at their proximal promoter. However, the 
intersection between H3K4me1 and H3K27Ac, to distinguish active and poised 
enhancers, showed that 99% of regions with reduced H3K27Ac was on active 
enhancers. A marked decrease of H3K27Ac on YY1-bound active enhancer was 
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identified in probands, and YY1 fold changes with H3K27Ac in active enhancer were 
positively correlated (p < 2.2 × 10−16) (Figure 56B) Moreover, after normalization on 
library size, 82%  of YY1-bound enhancers showed a statistically significant decrease 
in H3K27ac ( Figure 56C), while only 25% of the other active enhancer show a 
reduction in H3K27ac.  
 
Figure 56 YY1 Haploinsufficiency causes enhancer dysregulation. A) PCA of the H3K27ac read-count 
distribution. B) Loss of H3K27ac at YY1-bound compared to non-YY1-bound enhancers. P-value calculated 
with two-tailed test. C) Distribution of H3K27ac read densities at YY1-bound enhancer. RPKM: reads per 
kilobase pair per million reads mapped. Adapted from Gabriele et Al. 2017.  
These results are consistent with the already present evidence that YY1 mediates 
long-range interactions (Gerasimova et al., 2015; Medvedovic et al., 2013), 
subsequently confirmed by Young group (Weintraub et al., 2017). Consequently, the 
possibility that YY1 binding at distal enhancers might have a stronger impact on 
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gene expression, was tested. Following this assumption, of the YY1 binding sites not 
mapped in the proximal promoters, 65% were located on active enhancer, while only 
<4% were located on poised enhancers (identified by the simultaneous presence of 
H3K27me3 and H3K4me1). Also, 82% of YY1-bound enhancers showed a 
statistically significant decrease in H3K27ac, in contrast with merely 25% of the 
other active enhancers. Moreover, while no global increase of H3K27me3 was found, 
across YY1-bound regions the loss of H3K27ac is associated with an increase in 
H3K27me3, especially in regions with enrichment for these two histone 
modifications  (Figure 57). 
 
Figure 57 A) Foldchanges of H3K27ac and H3K27me3 across all YY1-enriched regions. B) H3K27ac and 
H3K27me3 foldchanges across YY1- bound regions with an enrichment for H3K27me3 and H3K27ac in at least 
one sample. The red line: smooth spline fitted on the data. 
 
Taking in account the 500 YY1 peaks least affected by its dosage, only 15% of 
overlapping enhancers showed a reduction of H3K27Ac, highlighting its cis role in 
regulating enhancer activation. For this reason, publicly available Hi-C profiles of 
LCL (Rao et al., 2014) were used to identify chromatin loops responsible for linking 
distal regulatory sites to TSS of putative genes. Following this analysis, 545 genes 
distally bound by YY1 were identified, of these set 206 are also bound at the TSS 
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(Gabriele et al., 2017). Interestingly, when compared with proximally genes, distally 
YY1-bound genes were much more likely to be differentially expressed (p ∼ 1.5 × 
10−5, chi-square test). In addition, distally YY1-bound genes were enriched with 
differentially expressed genes (p ∼ 6 × 10−8 with respect to the whole genome and p 
∼ 7 × 10−4 with respect to the expressed genes, hypergeometric test) (Gabriele et al., 
2017). These observation underscore that regardless of its preferential enrichment 
at the TSS, YY1 affects disproportionately more its distal targets. 
Treatment with histone deacetylase SAHA increases the 
expression of differentially acetylated genes in YY1 mutated 
samples  
Given the widespread loss of H3K27Ac in YY1 probands, the histone deacetylase 
inhibitor SAHA was adopted to treat controls and probands LCLs to test its 
capability of recovery gene expression.  Following overnight treatment with SAHA 
0,1 µM gene expression was evaluated in two differentially H3k27 acetylated, 
differentially expressed, and differentially YY1-bound genes (FAM179B and 
SUPT3H), and two classical housekeeping genes (TUBB and TBP) neither 
differentially acetylated nor differentially expressed but bound by YY1. RT-qPCR 
results shown in Figure 58 show that only probands are sensitive to this treatment 
and, compared with DMSO, expression levels are increased for all four tested genes.    
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Figure 58 YY1 mutated samples show increase expression levels after treatment with histone deacetylase 
inhibitor SAHA.  
 
YY1 patient-derived iPSCs show a selected deregulation 
To study the impact of YY1 mutations in more appropriate disease-relevant cell 
types, LCL of probands and controls, and a fibroblast samples of individual eight 
were subjected to reprogramming into iPSCs using Sendai virus. Sendai 
reprogramming was successful only in the fibroblast sample and in one proband and 
controls’ LCL. After reprogramming from LCL, Epstein Barr virus (EBV) expression 
in iPSCs was evaluated. Both samples completely turned off EBV expression 
compared to a positive control cDNA taken from LCL, showing irrelevant Ct, and 
with melting curves comparable with the negative (no cDNA), as shown in Figure 
59.  
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Figure 59 iPSCs derived from LCL turn off EBV genes. Melting courve for a positive control cDNA taken from 
LCL, the two iPSCs derived from LCL, and no cDNA control. 
The two YY1 iPSCs, the control iPSC LCL-derived, and one unmatched control 
reprogrammed previously with an independent reprogramming method (Adamo et 
al., 2015) were subjected to RNA-seq for genome wide-transcription analysis. First, 
the level of pluripotency genes was evaluated. All samples express comparable levels 
of NANOG, POU5F1 (OCT4), and SOX2 as depicted in Figure 60.  
 
Figure 60 iPSC derived from LCL and fibroblasts of controls and YY1 probands express a similar level of 
pluripotency gene and ACTB as housekeepings. Data showed Log normalized read counts. 
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Differential expression analyses identified 795 differentially expressed genes 
(DEGs) (FDR <0,25);  271  DEGs (FDR <0,1); 131 DEGs (FDR <0,0,5), represented 
in Figure 61 
To identify gene with high robustness the differentially expressed genes in GADEVS 
iPSCs,  
Differentially expression analysis between probands and control lines idenfied 236 
DEGs (Figure 61).  
 
Figure 61 DEA of YY1 iPSCs and CTL iPSCs. 131 differentially expressed genes with FDR <0,05. Scalebar 
represent lognormalized gene counts.  
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DISCUSSION  
KMT2D haploinsufficiency unveil transcriptional 
vulnerability in disease-relevant cell types 
Heterozygous mutations on KMT2D causes KS, of which clinical features are 
supposed to have origins mostly from altered development of cortical neurons 
(intellectual disability) and neural crests (systemic abnormalities and facial 
features). Here we describe for the first time a human KMT2D heterozygous 
modeling platform that appears to recapitulate molecular deregulations underlying 
KS clinical traits. We assembled a uniquely informative patient cohort composed of 
fibroblast biopsies from seven KS patients and five half-matched healthy controls. 
The first characterization of primary fibroblasts did not show any alteration of the 
bulk H3K4 methylation statuses, in line with previous reports that showed how 
KMT2D KO does not affect bulk deposition of H3K4me1 in the presence of two 
copies homolog KMT2C. Nevertheless, it was only showed a partial redundancy, 
with two very distinct phenotypes when one of the two was constitutively KO. (Lee 
et al., 2013b). Indeed, to identify specific deregulation caused by KMT2D 
heterozygosity, fibroblast were characterized transcriptionally. Already at this stage 
was possible to identify transcription dysregulation enriched for processes relevant 
to KS. Afterward, genome-wide H3K4me1 profiling was able to separate patients 
and controls according to the genotype, and a major defects on 7455 regions was 
identified. The loci with H3K4me1 loss were enriched in intergenic regions, pointing 
to the involvement of KMT2D in enhancer regulation. To validate this defect in 
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independent fibroblast datasets, we crossed our data with Roadmap epigenomics 
(Kundaje et al., 2015). This intersection confirmed a loss of monomethylation in 
regions commonly marked with this PTM, and we also identified the presence of an 
excess of H3K4me1 in regions commonly marked by H3K27me3. Although we have 
found a molecular scar indicative of KMT2D heterozygosity, dermal fibroblasts are 
not a cell type majorly affected in KS, and not suitable for extensive analysis given 
the limited cell division before they undergo senescence. For this reason, fibroblast 
samples were reprogrammed into iPSCs. KMT2D heterozygosity did not apparently 
interfere with the reprogramming process. In the iPSCs, we identified a comparable 
number of DEGs found in fibroblast, but differently from these, at the pluripotency 
stage, no enrichment was detected. Indeed, unsupervised clustering showed that 
each iPSCs clone was correlating with other clones of the same individual and the 
same family, suggesting that the differences among individual due to genetic 
background were overriding the effect of KMT2D heterozygosity. Genome-wide 
characterization of H3K4me1 and H3K27ac showed a separation between controls 
and mutated individuals in the former one, while no clear separation with very 
selective deregulated regions in the latter one. This evidence is compatible with the 
fact that KMT2D does not appear to be differentially deregulated in pluripotency 
and is in line with previous research that showed KMT2D to be necessary after 
gastrulation (Lee et al., 2013b). The results obtained from iPSCs characterization 
support evidence showing that KMT2D is needed later in development to an 
epigenetic stated required to establish or maintain differentiated cell state (Siang-
Yun Ang et al., 2016; Kim et al., 2016; Lee et al., 2013b) and that to the fact that 
somatic reprogramming is able to delete previous epigenetic signature derived from 
genetic and environmental factors (Mertens et al., 2015) de facto creating a new 
starting point. For this reason, iPSCs were differentiated to NCSC and cortical 
neurons to reproduce the recapitulate developmental stages and to identify the cell 
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stage at which deregulation responsible for the clinical phenotype occur. 
Transcriptome KS and controls NCSCs does not segregate by genotype samples. 
Regardless of this, it was possible to identify a set of deregulated genes, with a subset 
of genes recurrently identified changing analysis parameters. This small subset of 
genes was significantly enriched for the biological process cell adhesion. Worth of 
mention is that several of these genes are important for NC biology and KS clinical 
symptoms, For instance, FGF2, necessary for NCSC proliferation; ITGA10, an 
adhesion protein highly expressed in chondrocytes, COL9A3, which is associated 
with a developmental syndrome (OMIM # 600969), AP1S2, associated with mental 
retardation (OMIM #304340), ANO5, mutated in muscular dystrophies (OMIM # 
613319, .611307) and gnathodiaphyseal dysplasia (OMIM # 166260); FRAS1, known 
to be responsible for a recessive  multisystem disorder characterized by craniofacial, 
urogenital and respiratory anomalies (OMIM # 219000); TNS2, required for kidney 
function (Cho et al., 2006). Also, the whole set of DEGs is enriched for several 
categories relevant for KS pathogenesis associated with NC-derived tissues. At the 
stage of NCSC KMT2D appears slightly downregulated when compared to controls, 
but the variability among controls did not permit to make statistical claims. Profiling 
of chromatin modification H3K4me1 and H3K27Ac did not identify any dramatic 
alteration. Nevertheless, some deregulated enhancers were targeting genes 
fundamental for NCSC development and differentiation such as PAX8 (Blake and 
Ziman, 2014); NEDD4L, responsible for an autosomal dominant ND caused by a 
defect in neuronal migration(OMIM: #617201), SLITRK1, found mutated in a subset 
of Tourette syndrome patients (OMIM: # 137580) and a neuropsychiatric disorder 
(OMIM: #613229). Remarkably, the mild phenotype that we observed in NCSC is in 
line with a recent line of research that shows that in KS the fate of NCSC is mainly 
affected only in the post-migratory stage, when NCSC further differentiate in other 
cell types (Shpargel et al., 2017) 
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To understand how KMT2D mutations lead to intellectual disability we 
differentiated iPSCs into upper cortical layer excitatory neurons. Morphology of 
neuronal network was not found to be altered when compared to control samples. 
The spontaneous electrical activity of network burst showed a very specific 
phenotype distinct from controls and any other ND to when compared to Kleefstra 
syndrome, caused by mutations in EHMT1 but also KMT2C (Frega et al., 2018; 
Gabriele et al., 2018). This unique, spontaneous electrical network activity was 
identified by the presence of multiple firing bursts for each network burst, 
characteristic that lacks healthy individuals. Given the fact that neuronal 
architecture is not responsible for this striking phenotype, we investigated the 
molecular alterations of transcription and chromatin regulation. In iNeurons 
KMT2D is significantly downregulated with a logFC of -0,79. In a phenomenon that 
seems a clumsy attempt of compensating, KDM6A results upregulated with a logFC: 
0.9506504. Cortical neurons appear to degrade the mutant KMT2D allele through 
NMD fully. The lack of an efficient antibody does not permit to verify this 
observation ad the protein level. In cortical neurons we identified 1318 DEGs with 
an FDR < 0,05. These genes are enriched for categories relevant for neuronal 
electrophysiology, signal transduction, and translation. Importantly, by separating 
up and downregulated genes is possible to describe a specific impact of these two 
categories. While downregulated genes are responsible for the enrichment specific 
for neuronal function, upregulated genes are responsible for upregulation of mRNA 
metabolism and translation initiation. Remarkably, a flawed protein translation is 
an hallmark of intellectual disabilities such as autism (Rogozin et al., 2018; Torre-
Ubieta et al., 2016). Using a tool of the Ingenuity pathway analysis is possible to 
investigate diseases related to a gene subset. Remarkably, while upregulated genes 
were associated with categories related to cell death of cancer death and protein 
translation, the top categories in downregulated genes are associated with 
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melanoma and gastrointestinal cancer. Specifically, the tumor suppressor genes 
TP53, ATM, BAX, KLF10, and CDK1A are upregulated. It is relevant to discuss in 
detail a number of oncogenes resulted downregulated found in several disease 
ontology related to cancer from IPA analysis. These genes are listed in the following 
table:  
Table 7 oncogenes downregulated in KS iNeurons 
gene role cancer involvment  
Germline 
mutations 
Reference 
RET 
receptor tyrosine 
kinase 
Constitutively activated 
in multiple endocrine 
neoplasia type 2;  
Hirschsprung 
disease  
 
(Plaza-
Menacho et al., 
2006) 
MET 
tyrosine-protein 
kinase 
Constitutively activated 
by somatic and 
germline mutations in a 
broad variety of tumors 
Downregulated in 
Autism 
(Campbell et 
al., 2006; 
Comoglio et 
al., 2018) 
WNT5A  Wnt Ligand 
Upregulated in a 
variety of tumors  
Robinow 
syndrome 
(Asem et al., 
2016; Robinow 
et al., 1969) 
INO80D 
Chromatin 
remodeller 
Oncogenic in non-small 
cell lung cancer  
(Zhang et al., 
2017) 
KRAS 
RAS GTPase-
activating protein 
Oncogenic in non-small 
cell lung cancer and a 
variety of tumors 
Noonan 
syndrome, 
cardio-facio-
cutaneous 
syndrome 
(Haigis, 2017; 
Niihori et al., 
2006; Román 
et al., 2018; 
Schubbert et 
al., 2006) 
KSR2 
Scaffold regulator 
for MAPK 
 Overexpressed in 
melanoma and sustain 
tumor metabolism 
Early-onset 
obesity and 
severe insulin 
resistance 
(Bottiglione 
and Giurisato, 
2015; 
Fernandez et 
al., 2012; Guo 
et al., 2017) 
Rab27B 
Ras superfamily of 
monomeric G 
proteins 
Breast cancer 
progression  
(Chua and 
Tang, 2015) 
RAB31 
Ras superfamily of 
monomeric G 
proteins 
 Upregulated in breast, 
and cervical cancer, 
glioblastoma 
progression   
(Chua and 
Tang, 2015) 
POU5F1B OCT4 pseudogene 
Amplified in aggressive 
gastric cancer 
phenotype    
(Hayashi et al., 
2015) 
SOX11  Transcription factor 
Promotes breast 
cancer, and 
suppresses gastric 
cancer progression 
Mild Coffin-Siris 
syndrome 
(Oliemuller et 
al., 2017; QU 
et al., 2014; 
Shepherd et 
al., 2016; 
Tsurusaki et 
al., 2014) 
SOX4  Transcription factor 
 Oncogenic role in 
acute myeloid and 
lymphoblastic leukemia  
(Ramezani-
Rad et al., 
2013; H. 
Zhang et al., 
2013) 
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From this data it appears that MAPK pathway result deregulated. A number of 
oncogenes, listed in Table 7, is aligned with the theory of the inverse comorbidity 
(Tabarés-Seisdedos and Rubenstein, 2013) and while somatic overexpression leads 
to cancer, germline loss of function mutations lead to NDs, of which Robinow 
syndrome and Noonan syndrome share abnormalities that affect similar anatomical 
systems also affected in KS. Moreover, germline alteration of the MEK/ERK 
pathway were previously found responsible for KS. Indeed, homozygous mutations 
in RAP1A and heterozygous mutations RAP1B have been found responsible for KS, 
and RBBP5 was found to bind the promoter of RAP1B (Bögershausen et al., 2015). 
Moreover, biochemical studies involving the mutated RAP1A showed a reduced level 
of activation of MEK/ERK through BRAF activation and a reduced level of ERK 
pathway thorough RAF1 inhibition (Bögershausen et al., 2015).  Remarkably, in our 
iNeuron datasets RAP1GAP2,  a RAP1 activating GTPase (Schultess et al., 2005), 
results downregulated.  Importantly, KMT2D mutations have been found 
tumorigenic in melanoma (Bossi et al., 2016), associated with poor prognosis in 
Non-small-cell lung cancer (Ardeshir-Larijani et al., 2018),  frequently mutated in 
Small Cell Lung Cancer and diffuse large B-cell lymphoma (Augert et al., 2017; 
Pasqualucci et al., 2011), inactivated in blood, large intestine, and brain tumors but 
associated with poor prognosis of breast cancer (Rao and Dou, 2015). 
Contrary to what expected, with the exception of very few cases of KS with tumors, 
it does not seem that KS confers an increased cancer incidence when compared to 
the general population (Casanova et al., 2011). Therefore, it is tempting to speculate 
that KMT2D mutations impact cell identity with a very time-specific effect. While 
somatic mutations lead to cancer, it seems that germline mutations create an altered 
molecular environment that leads to KS but compensate preventing cancer onset. 
Our data from iNeurons supports this hypothesis since several oncogenes appear to 
be downregulated, and essential tumor suppressors are upregulated. Among these 
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upregulated tumor suppressors, the most probable candidate responsible for this 
compensation is KDM6A, not only because it is a direct interactor of KMT2D, but 
also because it was recently identified as a tumor suppressor protein, given its 
capability of counteracting PRC2 (Wang et al., 2018). Consequently, it is appealing 
to suggest that overexpression of KDM6A in terminally differentiated post-mitotic 
cell types, together with the downregulation of oncogenes and MAPK pathway, 
might be responsible for the lack of increased cancer susceptibility in KS patients. 
The density of genome-wide distribution of H3K4me1 did not appear to be strikingly 
affected. Nevertheless, quantitative analyses identified genomic regions 
corresponding to putative enhancers, which target genes are enriched for biological 
categories relevant for the neuronal biology. On the other hand, the analysis of 
H3K27Ac, with the exception of a sample, segregates KS individuals and controls 
according to their genotype. Genomic density distribution for this PTM shows a 
reduction of H3K27Ac in regions with high density of this mark and enrichment in 
some regions with a low density. Quantitative analysis of target genes of putative 
enhancer regions with loss or gain of H3K27Ac showed that hypoacetylated 
enhancers regulate genes related to KS neurological phenotype. On the other hand, 
hyperacetylated enhancers seem to regulate genes important for melanocytes or 
associated with a muscular function, such as contractile fiber and sarcoplasm. 
Similar results were recently shown by an independent line of research of our 
laboratory, in which it was demonstrated that the lack of KMT2B during trans-
differentiation from mouse embryonic fibroblast to neurons lead to imperfect 
transdifferentiation with overexpression of genes related to muscular function 
(Barbagiovanni et al., 2018).  
Using an internal database to identify master regulator upstream to gene networks 
is possible to use RBBP5 as a proxy to identify the putative direct target of KMT2D 
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for DEGs. By doing this analysis, we identified that 98 of the DEGs with a loss of 
H3K27Ac are putative targets of RBBP5, while 140 DEGs have a gain in H3K27Ac. 
The putative direct targets with a defect of enhancer activation are enriched in specific 
genes for neuronal function. On the other hand, the putative direct target of RBBP5 of 
the regions with a gain of H3K27Ac appears to be directly responsible for the 
enrichment for contractile fiber and sarcoplasm categories, since the subtraction of 
these genes to the set of genes erases such enrichment. Taken together, all these 
observations across several cell types are in line with recent evidence that shows that 
KMT2D catalytical activity is not necessary for its role in transcription 
regulation(Dorighi et al., 2017; Rickels et al., 2017). Indeed, only in the cell type with 
a complete KMT2D downregulation, in which the protein level is presumably 
halved, the most robust phenotype was detected both at functional and molecular 
level.  This advancement of the understanding of the KS molecular pathology, the 
identification of strong molecular and physiological phenotype, and the possibility 
of reproducing disease-relevant cell types, permits us now to design realistic 
strategy  to intervene in actionable pathways, to find molecular intervention able to 
revert the phenotype and, in parallel, to create a better understanding for the 
tumorigenic processes that underly somatic KMT2D mutations.  
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Discussion of results for YY1 haploinsufficiency  
We described for the first time a new neurodevelopmental disorder caused by 
haploinsufficiency of YY1, later named Gabriele-deVries syndrome (OMIM: # 
617557), which can result from its deletion or from single nucleotide mutations 
causing either missense mutations in the DNA-binding domain, or truncating 
mutations. The latter ones trigger NMD, leading to the degradation of the mutant 
transcript. By ChIP-seq with two independent antibodies, we showed that YY1 
deletion and missense and nonsense mutations equally impair YY1 chromatin 
binding, affecting mostly the low-occupancy sites supporting the proposed model 
for which YY1 haploinsufficiency cause the syndrome.  
According to the capability of YY1 to mediate chromatin loops between enhancers 
and promoters (Gabriele et al., 2017; Gerasimova et al., 2015; Medvedovic et al., 
2013; Weintraub et al., 2017),  individuals harboring YY1 mutations and deletions 
display an extensive loss of H3K27Ac on YY1-bound enhancers. These line of 
evidence supports the classification of Gabriele-de Vries syndrome as an 
enhanceropathy.  
In agreement with the observations that mutations in chromatin and transcriptional 
regulators severely impacts the neurodevelopment leading to a variety of 
neurodevelopmental disorders, given the vulnerability of this developmental stage 
and cell types to transcription regulation (Gabriele et al., 2018), and in agreement 
with the role in enhancer-promoter looping, YY1 has been shown to be involved in 
mediating enhancer-promoter looping in genes specific for mouse neuronal 
precursor (Beagan et al., 2017). In addition, YY1 has been shown to interact with the 
lncRNA Sox2ot, coded in the same locus of Sox2, and mediates Sox2 repression 
during the transition from neuronal precursor to neuronal differentiation. In this 
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context, YY1 downregulation was found to increase neural precursor population 
over early- and late-born neurons (Knauss et al., 2018).  
These pieces of evidence further support the haploinsufficiency of YY1 to be 
causative of intellectual disability, a foundational phenotype shared across all 
Gabriele-deVries patients, that failures thus likely cause it in orchestrating the 
stages of neural development. Given the higher vulnerability of YY1 mutated 
individuals to respond to histone deacetylase inhibitors (HDACs) it becomes 
pertinent to test this class of compounds in disease-relevant cell types such as 
cortical neurons.  
In this study we adopted LCL and iPSCs which are a good model to study YY1 
haploinsufficiency but not the most appropriate cell type of studying 
neurodevelopment. Indeed, shortly iPSCs will be differentiated in cortical neurons, 
as done for Kabuki syndrome, to address the specific impact of YY1 mutations in 
neurodevelopment. Nevertheless, since it was previously shown that the 
dysregulation found at the pluripotency stage can be further amplified and 
propagated in more differentiated cell types (Adamo et al., 2015), and given the fact 
that Gabriele de-Vries and Kabuki syndromes are enhanceropaties, it has been 
investigated the possibility that genes already dysregulated at the pluripotency stage 
in GADEVS could be deregulated in Kabuki neurons. The intersection between KS 
iPSCs DEGS (907, FDR < 0,1) and GADEVS iPSCs DEGs (271, FDR < 0,1) identified 
51 overlapping genes between the two conditions (hypergeometric test FDR ~ 
0,008). Moreover, the intersection of this subset of genes with DEGs (FDR < 0,1) in 
KS iNeurons identifies 1o genes that area also DEGs in this differentiated cell type, 
of which some are already known to be involved in neurodevelopmental diseases 
(Figure 62).   
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Figure 62 Expression profile of deregulated genes across disorders and cell types. Scalebar: log norm counts. 
 
These genes are PPIP5K2, PGM1, FAM200B, and MAN2B1. It is relevant to 
underscore that PPIP5K2, PGM1, and MAN2B1 are known to be associated with 
ASD, developmental delay, and a neurodevelopmental disorder, respectively. This 
preliminary analysis supports a model in which enhanceropaties caused by 
mutations in different genes converge towards regulatory pathways that may impact 
a subset of downstream genes responsible for the shared clinical manifestation. 
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